Orally Bioavailable Lipid-Based Constructs

Info

Publication number: 20100080773
Type: Application
Filed: Mar 27, 2009
Publication Date: Apr 1, 2010
Applicant:
Inventors: W. Blair Geho (Wooster, OH), John R. Lau (Howard, OH)
Application Number: 12/413,293

Abstract

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

Description

Description

PRIORITY

This application is a continuation in part of PCT application PCT/US08/77990, filed on Sep. 26, 2008, which in turn claims priority to U.S. patent application Ser. No. 11/904,937, filed on Sep. 28, 2007, each of which is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

One of the most preferred ways to deliver a pharmaceutical to a subject is in an oral formulation. However, oral formulations of many pharmaceutical compounds are often unavailable due to the pharmaceutical's incompatibility with the harsh environment of the digestive tract. This is particularly true for pharmaceutical compounds such as peptides, proteins, certain small molecules, and nucleic acids. Representative examples include calcitonin, serotonin, parathyroid hormone, GLP-1, erythropoietin, interferon of various types, human growth hormone, monoclonal antibodies, and many others, the utilities of which have been extensively reviewed in the literature.

Thus, what is needed in the field of oral drug delivery is a composition that enables oral delivery of a wide range of pharmaceutical products and other therapeutic agents. The present invention meets and addresses this need.

BRIEF SUMMARY OF THE INVENTION

The present invention includes compositions that facilitate and/or enable absorption of therapeutics which are not typically orally bioavailable. In one embodiment, a composition of the invention functions by associating with a therapeutic agent and chaperoning or escorting the therapeutic agent through the lumen of the gut into the portal blood flow and finally on to the systemic circulation. In certain embodiments, the composition of the invention possesses many unique and advantageous properties. One of these properties is the ability to insert into intercellular gaps and pass through the mammalian gut into the portal circulation. In certain embodiments, a composition of the invention may be targeted to specific cellular or extra-cellular receptors via one or more targeting agents. As an alternative to incorporation of a targeting agent, or optionally in addition to a targeting agent, a composition of the invention may further include one or more RES masking agents.

In a typical embodiment, an orally bioavailable composition of the invention comprises various lipid-based constituents, at least one therapeutic or diagnostic agent, an optional targeting agent, and/or an optional RES masking agent.

The various lipid-based constituents include, but are not limited to, dynamically sized liposomes, dynamically sized liposome fragments, and dynamically sized lipid particles. A lipid particle comprises at least one, but preferably more than one, molecule of a single lipid. A liposome or liposome fragment comprise at least two structurally unique lipid molecules. These lipid-based constituents may be formed when lipids are combined according to the procedures set forth herein.

In certain embodiments, the lipids are selected from the group consisting of MPB-PE, MCC-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate.

In certain embodiments, the therapeutic agent is selected from the group consisting of insulin, interferon, erythropoietin, parathyroid hormone, calcitonin, serotonin, rituximab, trastuzumab, uricase, tissue plasminogen activator, thymoglobin, a vaccine, heparin or a heparin analog, antithrombin, III, filgrastin, pramilitide acetate, exanatide, epifibatide, antivenins, IgG, IgM, HGH, thyroxine, GLP-1, blood clotting Factors VII, VIII, IX, Kallikrein, Kininogen, Hageman Factor (XII), plasma thromboplastin antecedent Factor (XI), tissue factor, Stuart Factor (X), accelerin (V), prothrombin (II), and fibrin stabilizing Factor (XIII); a monoclonal antibody, and glycolipids that act as therapeutic agents.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of preferred embodiments of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.

FIG. 1 is a schematic representation of a composition of the invention.

FIG. 2 is a graph depicting the counts of ¹⁴C radio-labeled phospholipid found in the femoral and portal veins 15 and 30 minutes post injecting radio-labeled composition into the duodenum of a fasted and anesthetized 230 gram rat.

FIG. 3 is a bar graph depicting the distribution of ¹⁴C radio-labeled phospholipid amongst the blood, liver, and spleen in the rats of FIG. 2, post-sacrifice.

FIG. 4 is a graph depicting the absorption of radio-labeled composition from drinking water at 15, 30, and 45 minutes post-dosing.

FIG. 5 is a bar graph depicting the distribution of the labeled composition amongst the blood, liver, and spleen in the rats of FIG. 4, post-sacrifice.

FIG. 6 is a graph depicting the efficacy of orally administered insulin in the form of a composition of the invention.

FIG. 7 is a bar graph depicting the efficacy of a composition of the invention (at low dosages), in converting a type 2 diabetic dog from hepatic glucose output to uptake during a portal glucose load.

FIG. 8 is a plot of blood calcium levels after the administration of calcitonin associated with a non-targeted composition of the invention.

FIG. 9 is a graph of the size distribution of the constituent members of a composition of the invention.

FIG. 10 is a graph of the efficacy of a composition of the invention comprising a biotin targeting agent and insulin at reducing the effects of type 2 diabetes in humans.

FIG. 11 is a chromatogram of a composition of the invention showing the efficacy of insulin loading.

FIG. 12 is a graph depicting the efficacy of oral delivery of IgG antibodies covalently linked to a composition of the invention versus oral absorption of non-associated (free) IgG antibodies.

FIG. 13 is a graph depicting the effect of oral administration of thyroxine associated with a composition of the invention on serum cholesterol and triglycerides (“TG”) in mice.

FIG. 14 is a graph depicting the effect of oral administration of interferon associated with a composition of the invention on reducing viral load in humans suffering from hepatitis-C.

DETAILED DESCRIPTION OF THE INVENTION

The present invention includes compositions that facilitate and/or enable absorption of therapeutics which are not typically orally bioavailable. The compounds of the present invention may further act to enhance the oral bioavailability of compounds that are already orally bioavailable. In one embodiment, a composition of the invention functions by associating with a therapeutic agent and chaperoning the therapeutic agent through the lumen of the gut into the portal blood flow and finally on to the systemic circulation. The composition of the invention possess many unique and advantageous properties. One of these properties is the ability to insert into intercellular gaps and pass through the mammalian gut into the portal circulation. In certain embodiments, a composition of the invention may be targeted to specific cellular or extra-cellular receptors via one or more targeting agents. As an alternative to incorporation of a targeting agent, or optionally in addition to a targeting agent, a composition of the invention may further include one or more reticuloendothelial system (“RES”) masking agents.

Although the present invention bears some resemblance to the composition disclosed in PCT/US06/19119, U.S. patent application Ser. No. 11/904,937, and PCT/US08/77990, the compositions of the present invention may be differentiated from all three applications. The present invention may be differentiated from PCT/U06/19119 by the size of the composition as well as the use of covalent linkages to tether a given therapeutic agent. The present invention may be differentiated from PCT/US08/77990 and Ser. No. 11/904,937 by the chemical structure of the linker used to link a given therapeutic agent to the composition. The present invention may be further differentiated from U.S. patent application Ser. No. 11/904,937 and PCT/US08/77990 by the therapeutic agent associated with the composition.

In a typical embodiment, an orally bioavailable composition of the invention comprises various lipid-based constituents, at least one therapeutic or diagnostic agent, an optional targeting agent, and/or an optional RES masking agent.

Definitions

Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry and protein chemistry are those well known and commonly employed in the art.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

As used herein, amino acids are represented by the full name thereof, by the three-letter code as well as the one-letter code corresponding thereto, as indicated in the following table:

3 Letter 1-Letter Full Name Code Code Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic Asp D Acid Cysteine Cys C Cystine Cys-Cys C-C Glutamic Glu E Acid Glutamine Gln Q Glycine Gly G Histidine His H Isoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V

The term “lower”, when used in reference to a chemical structure, describes a group containing from 1 to 6 carbon atoms.

The term “alkyl”, by itself or as part of another substituent means, unless otherwise stated, a straight, branched or cyclic hydrocarbon having the number of carbon atoms designated (i.e. C₁-C₆means one to six carbons). Examples include: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, cyclohexyl and cyclopropylmethyl. Most preferred is (C₁-C₃)alkyl, particularly ethyl, methyl and isopropyl.

The term “alkylene”, by itself or as part of another substituent means, unless otherwise stated, a straight, branched or cyclic chain hydrocarbon having two substitution sites, e. g., methylene(-CH₂—), ethylene(-CH₂CH₂—), isopropylene(-C(CH₃)═CH—), etc.

The term “aryl”, employed alone or in combination with other terms, means, unless otherwise stated, a carbocyclic structure, with or without saturation, containing one or more rings (typically one, two or three rings) wherein said rings may be attached together in a pendant manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl, and naphthyl. The structure may be optionally substituted with one or more substituents, independently selected from halogen; (C₁-C₆)alkyl; (C₁-C₆)alkenyl; (C₁-C₆)alkoxy; OH; NO₂; C≡N; C(═O)O(C₁-C₃)alkyl; (C₂-C₆)alkylene-OR²; phosphonato; NR²₂; NHC(═O)(C₁-C₆)alkyl; sulfamyl; carbamyl; OC(═O)(C₁-C₃)alkyl; O(C₂-C₆)alkylene-N((C₁-C₆)alkyl)₂; and (C₁-C₃)perfluoroalkyl.

The term “arylloweralkyl” means a functional group wherein an aryl group is attached to a lower alkylene group, e.g., —CH₂CH₂-phenyl.

The term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group or an alkyl group containing a substituent such as a hydroxyl group, having the designated number of carbon atoms connected to the rest of the molecule via an oxygen atom, such as, for example, —OCH(OH)—, —OCH₂OH, methoxy(-OCH₃), ethoxy(-OCH₂CH₃), 1-propoxy(-OCH₂CH₂CH₃), 2-propoxy(isopropoxy), butoxy(-OCH₂CH₂CH₂CH₃), pentoxy(-OCH₂CH₂CH₂CH₂CH₃), and the higher homologs and isomers.

The term “acyl” means a functional group of the general formula —C(═O)—R, wherein —R is hydrogen, alkyl, amino or alkoxy. Examples include acetyl(-C(═O)CH₃), propionyl(-C(═O)CH₂CH₃), benzoyl(-C(═O)C₆H₅), phenylacetyl(C(═O)CH₂C₆H₅), carboethoxy(-CO₂CH₂CH₃), and dimethylcarbamoyl(C(═O)N(CH₃)₂).

The terms “halo” or “halogen” by themselves or as part of another substituent mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

The term “heterocycle” or “heterocyclyl” or “heterocyclic” by itself or as part of another substituent means, unless otherwise stated, a saturated or unsaturated, stable, mono or multicyclic ring system comprising carbon atoms and at least one heteroatom selected from the group comprising N, O, and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. Examples include pyridine, pyrrole, imidazole, benzimidazole, phthalein, pyridenyl, pyranyl, furanyl, thiazole, thiophene, oxazole, pyrazole, 3-pyrroline, pyrrolidene, pyrimidine, purine, quinoline, isoquinoline, carbazole, etc. Where substitution will result in a stable compounds, the structure may be optionally substituted with one or more substituents, independently selected from halogen; (C₁-C₆)alkyl; (C₁-C₆)alkenyl; (C₁-C₆)alkoxy; OH; NO₂; C≡N; C(═O)O(C₁-C₃)alkyl; (C₂-C₆)alkylene-OR²; phosphonato; NR²₂; NHC(═O)(C₁-C₆)alkyl; sulfamyl; carbamyl; OC(═O)(C₁-C₃)alkyl; O(C₂-C₆)alkylene-N((C₁-C₆)alkyl)₂; and (C₁-C₃)perfluoroalkyl.

The term “amphipathic lipid” means a lipid molecule having a polar end and a non-polar end.

A “complexing agent” is a compound capable of forming a water insoluble coordination complex with a metal, e.g. a salt of chromium, zirconium, etc., that is substantially insoluble in water and soluble in organic solvents.

“Aqueous media” means media comprising water or media comprising water containing at least one buffer or salt.

The terms “associated,” or “associated with,” as well as variations thereof, when used in reference to a composition of the invention, means that the referenced material, typically a therapeutic agent, is incorporated (or intercalated) into, or on the surface of, or within a lipid-based constituent comprising the composition of the present invention. Association may, however, refer to the situation wherein the referenced material, typically a therapeutic agent, is covalently attached to a lipid included in one of the various lipid-based constituents comprising the composition of the invention. The applicability of the appropriate definition will be appreciable from the context in which the terms is used.

The term “insulin” refers to natural or recombinant forms of insulin, synthetic insulin, and derivatives of the aforementioned insulins. Examples of insulin include, but are not limited to insulin lispro, insulin aspart, regular insulin, insulin glargine, insulin zinc, human insulin zinc extended, isophane insulin, human buffered regular insulin, insulin glulisine, recombinant human regular insulin, ultralente insulin, humulin, NPH insulin, Levemir, Novolog, and recombinant human insulin isophane. Also included are animal insulins, such as bovine or porcine insulin.

The terms “glargine” and “glargine insulin” both refer to a recombinant human insulin analog which differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin and has the empirical formula C₂₆₇H₄₀₄N₇₂O₇₈S₆and a molecular weight of 6063.

The term “recombinant human insulin isophane” refers to a human insulin that has been treated with protamine.

The term “bioavailability” refers to a measurement of the rate and extent that a pharmaceutical agent, such as, but not limited to, insulin, reaches the systemic circulation and is available at its site of action.

As used herein, to “treat” means reducing the frequency with which symptoms of a disease, disorder, or adverse condition, and the like, are experienced by a patient.

As used herein, the term “pharmaceutically acceptable carrier” means a chemical composition with which the active ingredient may be combined and which, following the combination, can be used to administer the active ingredient to a subject.

The term “lipid” or “lipids” means an organic compound characterized by its preference for non-polar solvents. A lipid may or may not possess an alkyl tail. Lipids according to the present invention include, but are not limited to, the class of compounds known in the art as phospholipids, cholesterols, and dialkyl phosphates.

As used herein, “cholesterol” means the compound and all derivatives and analogs of the compound:

wherein said derivatives and analogs include, but are not limited to, thiocholesterol:

As used herein, “1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol” means the compound having the formula:

as well as salts thereof.

As used herein, “particle” comprises an agglomeration of multiple units of one or more lipids.

As used herein, “thyroxine” refers to the compound:

wherein the amino group may be in either the “D” or “L” configuration.

As used herein, “co-administration” or “co-administering” as well as variations thereof, means administering a second therapeutic agent before, during, or after the administration of a first therapeutic agent. The first and second therapeutic agents may be the same or different.

As used herein, “interferon” refers to all forms of interferon, including, but not limited to, interferon-α, interferon-beta, interferon-gamma, as well as sub-units thereof.

Description

A composition of the present invention is comprised of various lipid-based constituents, at least one therapeutic or diagnostic agent, optionally at least one targeting molecule, and optionally, at least one RES masking agent. A composition of the present invention may further include gelatin as an active component. When present, the gelatin actively reversibly interacts with one or more of the various lipid-based constituents to stabilize the composition of the invention. The at least one therapeutic agent and/or diagnostic agent is associated with a lipid-based constituent comprising the composition of the invention.

The lipid-based constituents comprising a composition of the invention include, but are not limited to, dynamically sized liposomes, dynamically sized liposome fragments, and dynamically sized lipid particles. A lipid particle comprises at least one, but preferably more than one, molecule of a single lipid. A liposome or liposome fragment comprise at least two structurally unique lipid molecules.

Traditionally, liposome, liposome fragments, and lipid particles comprised of amphipathic materials have been limited to a lower size distribution of about 40 nanometers. This limit was believed to be a function of the collective sizes of the constituent lipids (phospholipids, cholesterols, dialkylphosphates, etc.) that constituted the membrane structure.

The lipid-based constituents of a composition of the invention, however, demonstrate heretofore unobserved dynamic sizing and size elasticity. Specifically, these structures exist in a dynamic equilibrium in aqueous media such that, on average, these structures fluctuate in size from about 6 nanometers to about 80 nanometers in diameter, but may reach sizes as large as 200 nanometers. At any given time, anywhere from about 5% to about 50% of the various lipid-based constituents exhibit an average diameter of about 20 nanometers or less. Due to the nearly constant fluctuations in sizes, the lipid-based constituents cannot be physically separated by traditional fractionating means to form discrete populations.

The composition of the invention may associate with one or more therapeutic agents or diagnostic agents. When these associations are non-covalent, and without wishing to be bound by any particular theory, it is believed that a given therapeutic agent is associated with a composition of the invention through various intramolecular forces. It is further believed that when a lipid-based constituent comprising the composition of the invention has a diameter of 20 nanometers or less, it is sufficiently small to pass through intracellular gaps and enable the transport of the associated therapeutic agent from the lumen of the gut into the portal blood flow. Another mechanism of action may, however, account for the observed activity.

Lipids

The lipids comprising the composition of the present invention are selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, cholesterol oleate, thiocholesterol, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate, MPB-PE, MCC-PE, and derivatives thereof, including but not limited to salts. Representative structures are presented in Table 1.

TABLE 1 Common Name Chemical Name Structure 1,2-distearoyl- sn-glycero-3- phosphocholine 2,3- bis(stearoyloxy)propyl 2-(trimethylammonio) ethyl phosphate 1,2-dipalmitoyl- sn-glycero-3- phosphocholine 2,3- bis(palmitoyloxy)propyl 2-(trimethylammonio) ethyl phosphate 1,2-dimyristoyl- sn-glycero-3- phosphocholine 2,3-bis (tetradecanoyloxy) propyl 2- (trimethylammonio) ethyl phosphate Cholesterol 10,13-dimethyl-17- (6-methylheptan-2-yl)- 2,3,4,7,8,9,10,11,12,13, 14,15,16,17- tetradecahydro-1H- cyclopenta[a] phenanthren-3-ol MPB-PE (Na⁺ salt) 1,2-Dipalmitoyl-sn- glycero-3- phosphoethanol- amine-N-[4-(p- maleimido)phenyl- butyrate] MCC-PE (Na⁺ salt) 1,2-Dipalmitoyl-sn- glycero-3- phosphoethanol- amine-N-[4-(p- maleimido- methyl)cyclohexane- carboxamide]

By way of non-limiting examples, the lipid-based constituents comprising the composition of the invention may be formed from about 40 to about 65 mol % 1,2 distearoyl-sn-glycero-3-phosphocholine; from about 10 to about 50 mol % dihexadecyl phosphate; from about 15 to about 35 mol % cholesterol, and optionally up to about 15 mol %, preferably less than about 5 mol %, and most preferably about 1 mol % of a targeting agent. The amount of targeting agent necessary to target a given composition will be dictated by the size and structure of the therapeutic agent. It is within the skill level of the orididnary skill artisan, based on the disclosure herein, to select and prepare the composition of the invention containing the appropriate amount of targeting agent.

In a preferred embodiment, the lipid-based constituents comprising the composition of the invention are formed from approximately 62 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, and approximately 16 mole percent cholesterol. In certain variations of this embodiment, at least about 25% of the cholesterol may be thiocholesterol. In a further variation, at least about 50% of the cholesterol may be thiocholesterol. In yet another variation, at least about 75% of the cholesterol may be thiocholesterol. In a further variation, all of the cholesterol may be thiocholesterol.

In another embodiment, the lipid-based constituents comprising the composition of the invention are formed from approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and about 1 mole percent of at least one targeting agent. Up to an additional 1 mole percent of targeting agent may be added to this embodiment.

In a variation of this embodiment, at least about 25% of the cholesterol may be thiocholesterol. In a further variation, at least about 50% of the cholesterol may be thiocholesterol. In another variation, at least about 75% of the cholesterol may be thiocholesterol. In a further variation, all of the cholesterol may be thiocholesterol.

The lipid-based constituents comprising the composition of the invention may also be formed from 40 to 75 mole % 1,2 dipalmitoyl-sn-glycero-3-phosphocholine; from 5 to 50 mole % dihexadecyl phosphate; from 5 to 15 mole % cholesterol; from 1 to 6 mole % MPB-PE, MCC-PE, or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; and, optionally, up to about 2 mole %, but preferably not more than 1 mole percent of a targeting agent.

In a specific embodiment, the lipid-based constituents comprising the composition of the invention may be formed from approximately 68 mole % 1,2 dipalmitoyl-sn-glycero-3-phosphocholine, approximately 19 mole % dihexadecyl phosphate, approximately 10 mole % cholesterol, and approximately 3 mole % MPB-PE, MCC-PE, or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine. In certain variations of this embodiment, at least about 25% of the cholesterol may be thiocholesterol. In a further variation, at least about 50% of the cholesterol may be thiocholesterol. In another variation, at least about 75% of the cholesterol may be thiocholesterol. In a further variation, all of the cholesterol may be thiocholesterol.

When any of the cholesterol in any variation of this embodiment is thiocholesterol, and either MPB-PE or MCC-PE is present, MPB-PE or MCC-PE will have been reacted with an appropriate nucleophile prior to being exposed to thiocholesterol.

In each of the above described embodiments, up to about 10% of the 1,2 dipalmitoyl-sn-glycero-3-phosphocholine may be replaced with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine or 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol.

Each of the above described embodiments further includes at least one associated therapeutic agent or diagnostic agent. In certain embodiments, the therapeutic agent may be non-covalently associated with the composition. In alternative embodiments, the associated therapeutic agent may be covalently linked to a lipid incorporated into a lipid-based constituent comprising the composition of the invention. The process of covalently linking a therapeutic agent to a lipid is described elsewhere herein.

When therapeutic agents are attached via covalent linkages, it is preferred that therapeutic agents are linked to no more than about 10 mole % of the lipids comprising the composition of the invention. Even more preferably, therapeutic agents are linked to no more than about 5 mole % of the lipids comprising the composition of the invention. Most preferably, therapeutic agents are linked to no more than about 2 mole % of the lipids comprising the composition of the invention. Although the above described quantities are preferred, a person of ordinary skill in the art will be able to attenuate or titrate the amount of therapeutic agent present in or on a given composition in order to affect the amount of therapeutic agent delivered to a patient in need thereof.

Any of the above described embodiments may further optionally include one or more RES masking agents. Typically, the one or more RES masking agents are covalently attached, either directly or indirectly, to one or more of the lipids comprising the composition of the invention as is described elsewhere herein. They may, however, be non-covalently associated with a composition of the invention.

When covalently attached, RES masking agents are linked to no more than about 10 mole % of the lipids comprising the composition of the invention. Even more preferably, RES masking agents are linked to no more than about 5 mole % of the lipids comprising the composition of the invention. Most preferably, RES masking agents are linked to no more than about 2 mole % of the lipids comprising the composition of the invention.

When one or more RES masking agents are associated with a composition of the invention non-covalently, any of the above described embodiments may include up to about 10 mole % or greater of one or more RES masking agents.

Although it is preferred that a composition of the invention contain about 18 mole % up to about 22 mole % dihexadecyl phosphate, a composition of the invention may contain up to 30 mole %, even up to 40 mole %, and even as much as 50 mole % dihexadecyl phosphate, inclusive of any incremental amounts of dihexadecyl phosphate therein. This increase in the amount of dihexadecyl phosphate requires a concomitant reduction in the quantity of one or more other lipids in the composition by a total amount equivalent to the quantity of dihexadecyl phosphate added in excess of 18 or 22 mole %.

Preparation

Generally, the composition of the present invention is formed when appropriate lipids and other ingredients (such as a targeting molecule) are homogenized in an aqueous media via microfluidization or other process involving cavitation.

In an embodiment of the invention, the lipids and other ingredients may be homogenized in 18 mM phosphate buffer at a pH of about 6.0 to a pH of about 8.0. Lipid concentration in the phosphate buffer may range from about 10 to about 200 mg/ml and any and all whole and partial integers therebetween. In one embodiment, the lipid concentration is about 30 to about 150 mg/ml. In more preferred embodiment, the lipid concentration is about 15 to about 50 mg/ml. In a most preferred embodiment, the lipid concentration is about 28-30 mg/ml.

Homogenization of the aqueous media, lipids and other ingredients may be accomplished via treatment in a device suitable for homogenization. Examples of suitable devices include, but are not limited to, a Polytron® System PT 6100, an M-110-EH microfluidizer, an ultrasonic sonicator, a high pressure membrane filtration apparatus, and a homogenizer extruder.

In instances where a microfluidizer is used, the microfluidizer is preferably operated at a temperature that is greater than the highest transition temperature of the various lipids and most preferably at a temperature greater than about 75° C. The elevated temperature allows any acyl and alkyl chains present in the lipids to move fluidly as well as conform to and associate with neighboring hydrocarbon moieties. These non-covalent associations directly result in the formation of a constituent of a composition of the present invention.

For the microfluidization process, up to about five independent passes are required at 9000 psig in order to prepare compositions having lipid-based constituents sized from about 6 to about 200 nanometers, with the optimal size range being about 6 to about 80 nanometers, and the average size in this range being about 50 to about 60 nanometers. A significant percentage of the lipid-based constituents, are approximately 20 nanometers. Average sizing is measured by a Coulter N-4 Plus Sub-Micron Particle Size Analyzer. After microfluidization, the resulting constituents may be sterile filtered through a 0.8 micron to 0.2 micron gang Supor™ membrane at 50 to 70° C., preferably at about 60° C. FIG. 9 represents repeated size analyses on the same sample as it remained stationary in the Coulter N-4 Plus Sub Micron Particle Size Analyzer. This data demonstrates the dynamic sizing and fluid nature of the lipid-based constituents formed from the lipids comprising the invention.

During the process of sub-micron particle formation, hydrogen bonding, ionic bonding, van der Waal's interactions, dipolar interactions, ion-dipole interactions, hydrophobic associations, and thermodynamic considerations dictate the manner in which the lipids assemble. While not wishing to be bound by any one particular theory, it is believed that the interaction of all of these forces, to varying extents, under the conditions noted above, lead to a dynamically sized composition of the present invention.

Incorporation of a Targeting Agent

In certain embodiments, a composition of the present invention may optionally comprise a targeting agent. Targeting agents alter the composition's bio-distribution and further enhances the efficacy of an associated therapeutic agent. A composition of the present invention may incorporate one or more targeting agents that act to target the composition, and associated therapeutic, to a specific cellular or extracellular receptor. For example, a targeting agent may be used to target insulin associated with a composition of the invention to hepatocytes in order to control post-prandial glycogen storage.

In one embodiment, a targeting agent facilitates delivery of a therapeutic agent to the liver and encompasses a class of molecules referred to as “hepatocyte target molecule” (HTM). HTM examples include, but are not limited to, biotin-DHPE, biotin-X-DHPE, and metal derived targeting agents such as poly[Cr-bis(N-2,6-diisopropylphenylcarbamoylmethyl iminodiacetic acid)]. Metal-derived targeting agents and biotin derived targeting agents are discussed below and are fully described in U.S. Pat. Nos. 7,169,410 and 4,603,044; PCT application PCT/US06/19119; and U.S. patent application Ser. Nos. 11/384,728, and 11/384,659. Additional examples of biotin-derived targeting agents are disclosed in Table 2.

When the targeting agent comprises biotin, iminobiotin, carboxybiotin, biocytin, or iminobiocytin, the biotin, iminobiotin, carboxybiotin, biocytin, or iminobiocytin molecules may be bound via an amide bond to the nitrogen of a phospholipid molecule such as 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine. The compounds may likewise be bound to a molecule such as cholesterol through an ester linkage. In the case of biocytin and iminobiocytin, the compounds may be bound to benzoyl thioacetyl triglycine via an amide bond between the terminal nitrogen of iminiobiocytin and the terminal carbonyl of benzoyl thioacetyl triglycine. Alternative bond connectivities to those described above are possible and considered to be within the scope of the present invention.

TABLE 2 1 N-hydroxysuccinimide (NHS) biotin 2,5-dioxopyrrolidin-1-yl 5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4-d]imidazol- 4-yl)pentanoate 2 sulfo-NHS-biotin sodium 2,5-dioxo-3-(trioxidanylthio) pyrrolidin-1-yl 5-((3aS,6aR)-2-oxo- hexahydro-1H-thieno[3,4-d]imidazol-4- yl)pentanoate 3 N-hydroxysuccinimide long chain biotin 2,5-dioxopyrrolidin-1-yl 6-(5-((3aS,6aR)- 2-oxohexahydro-1H-thieno[3,4-d]imidazol- 4-yl)pentanamido)hexanoate 4 sulfo-N-hydroxysuccinimide long chain biotin sodium 2,5-dioxo-3-(trioxidanylthio)pyrro- lidin-1-yl 6-(5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanamido)hexanoate 5 D-biotin 5-((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl)pentanoic acid 6 Biocytin 2-amino-6-(5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanamido)hexanoic acid 7 sulfo-N-hydroxysuccinimide-S-S-biotin sodium 2,5-dioxo-3-(trioxidanylthio)pyrro- lidin-1-yl 3-((2-(4-((3aS,6aR)-2-oxo- hexahydro-1H-thieno[3,4-d]imidazol-4- yl)butylamino)ethyl)disulfanyl)propanoate 8 biotin-BMCC 4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1- yl)methyl)-N-(4-(5-((3aS,6aR)-2-oxo- hexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamido)butyl)cyclohexanecarboxamide 9 biotin-HPDP 5-((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl)-N-(6-(3- (pyridin-2-yldisulfanyl)propanamido)hexyl) pentanamide 10 iodoacetyl-LC-biotin N-(6-(2-iodoacetamido)hexyl)-5-((3aS,6aR)- 2-oxohexahydro-1H-thieno[3,4-d]imidazol- 4-yl)pentanamide 11 biotin-hydrazide 5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanehydrazide 12 biotin-LC-hydrazide N-(6-hydrazinyl-6-oxohexyl)-5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamide 13 biocytin hydrazide N-(5-amino-6-hydrazinyl-6-oxohexyl)-5- ((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamide 14 biotin cadaverine N-(5-aminopentyl)-5-((3aS,6aR)-2-oxohexa- hydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamide 15 Carboxybiotin (3aS,6aR)-4-(4-carboxybutyl)-2-oxohexahydro- 1H-thieno[3,4-d]imidazole-1-carboxylic acid 16 Photobiotin N-(3-((3-(4-azido-2-nitrophenylamino)propyl) (methyl)amino)propyl)-5-((3aS,6aR)-2-oxo- hexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamide 17 ρ-aminobenzoyl biocylin trifluoroacetate 2-(4-aminobenzamido)-6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4- yl)pentanamido)hexanoic acid 2,2,2-trifluoroacetate 18 ρ-diazobenzoyl biocytin 4-(1-carboxy-5-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamido) pentylcarbamoyl) benzenediazonium chloride 19 biotin DHPE G⁺ = Li⁺, Na⁺, K⁺, (Et₃NH)⁺ 2,3-diacetoxypropyl 2-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)ethyl phosphate 20 biotin-X-DHPE G⁺ = Li⁺, Na⁺, K⁺, (Et₃NH)⁺ 2,3-diacetoxypropyl 2-(6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)hexanamido) ethyl phosphate 21 12-((biotinyl)amino)dodecanoic acid 12-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanamido) dodecanoic acid 22 12-((biotinyl)amino)dodecanoic acid succinimidyl ester 2,5-dioxopyrrolidin-1-yl 12-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)dodecanoate 23 S-biotinyl homocysteine 4-mercapto-2-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamido) butanoic acid 24 biocytin-X 2-amino-6-(6-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamido) hexanamido)hexanoic acid 25 biocytin x-hydrazide N-(5-amino-6-hydrazinyl-6- oxohexyl)-6-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamido) hexanamide 26 Biotinethylenediamine N-(2-aminoethyl)-5-((3aS,6aR)- 2-oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamide 27 biotin-X 6-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanamido) hexanoic acid 28 biotin-X-ethylenediamine N-(2-aminoethyl)-6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)hexanamide 29 biotin-XX hydrazide N-(6-hydrazinyl-6-oxohexyl)-6- (5-((3aS,6ar)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4- yl)pentanamido)hexanamide 30 biotin-XX-SE 2,5-dioxopyrrolidin-1-yl 6-(6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)hexanamido) hexanoate 31 biotin-XX,SSE sodium 2,5-diono-1-(6-(6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4- yl)pentanamido)hexanamido) hexanoyloxy)pyrrolidine-3- sulfonate 32 biotin-X-cadaverine 5-(6-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanamido) hexanamido)pentan-1-aminium 2,2,2-trifluoroacetate 33 α-(t-BOC)biocytin 2-(tert-butoxycarbonylamino)-6- (5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanamido)hexanoic acid 34 N-(biotinyl)-N′- (iodoacetyl)ethylenediamine N-(2-(2-iodoacetamido)ethyl)-5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamide 35 DNP-X-biocytin-X-SE 2,5-dioxopyrrolidin-1-yl 2-(6- (6-(2,4-dinitrophenylamino) hexanamido)hexanamido)-6-(6- (5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanamido)hexanamido) hexanoate 36 biotin-X-hydrazide N-(6-hydrazinyl-6-oxohexyl)-5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamide 37 norbiotinamine hydrochloride 4-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) butan-1-aminium chloride 38 3-(N-maleimidylpropionyl)biocytin 2-(3-(2,5-dioxo-2,5-dihydro-1H- pyrrol-1-yl)propanamido)-6-(5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanamido)hexanoic acid 39 ARP; N′-(2-aminooxy)acetyl)-5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanehydrazide 40 biotin-1-sulfoxide 5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanoic acid sulfoxide 41 biotin methyl ester methyl 5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanoate 42 biotin-maleimide 6-(2,5-diono-2,5-dihydro-1H- pyrrol-1-yl)-N′-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno [3,4-d]imidazol-4-yl)pentanoyl) hexanehydrazide 43 Biotin-poly(ethyleneglycol)amine aminomethyl polyethylene 5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanoate 44 (+) biotin 4-amidobenzoic acid sodium salt sodium 4-(5-((3aS,6aR)-2- oxohexahydro-1H-thieno [3,4-d]imidazol-4-yl) pentanamido)benzoate 45 Biotin 2-N-acetylamino-2-deoxy- β-D-glucopyranoside ((2R,5S)-3-acetamido-4,5- dihydroxy-6-(hydroxymethyl)- 2,3,4,5,6-pentamethyltetrahydro- 2H-pyran-2-yl)methyl 5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanoate 46 Biotin-α-D-N-acetylneuraminide (2S,5R)-5-acetamido-4-hydroxy- 3,3,4,5,6-pentamethyl-2-((5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanoyloxy)methyl)-6-(1,2,3- trihydroxypropyl)tetrahydro- 2H-pyran-2-carboxylic acid 47 Biotin-α-L-fucoside ((2R,5S)-3,4,5-trihydroxy- 2,3,4,5,6,6- hexamethyltetrahydro-2H-pyran- 2-yl)methyl 5-((3aS,6aR)-2- oxohexahydro-1H-thieno[3,4- d]imidazol-4-yl)pentanoate 48 Biotin lacto-N-bioside See end of table for name 49 Biotin-Lewis-A trisaccharide See end of table for name 50 Biotin-Lewis-Y tetrasaccharide See end of table for name 51 Biotin-α-D-mannopyranoside ((1R,4R)-2,3,4-trihydroxy-5- (hydroxymethyl)-1,2,3,4,5- pentamethylcyclohexyl)methyl 5-((3aS,6aR)-2-oxohexahydro- 1H-thieno[3,4-d]imidazol-4-yl) pentanoate 52 biotin 6-O-phospho-α-D- mannopyranoside ((2R,5S)-3,4,5-trihydroxy- 2,3,4,5,6-pentamethyl-6- (phosphonooxymethyl)tetra- hydro-2H-pyran-2-yl)methyl 5- ((3aS,6aR)-2-oxohexahydro-1H- thieno[3,4-d]imidazol-4-yl) pentanoate

Names of Compounds 48-50:

48. ((2R,5S)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-2,3,4,6-tetramethyl-4-((((2S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2,3,4,5,6-pentamethyltetrahydro-2H-pyran-2-yl)methoxy)methyl)tetrahydro-2H-pyran-2-yl)methyl 5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate((2R,5S)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-2,3,4,6-tetramethyl-4-((((2S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2,3,4,5,6-pentamethyltetrahydro-2H-pyran-2-yl)methoxy)methyl)tetrahydro-2H-pyran-2-yl)methyl 5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate.

49. (2R,3R,5S)-5-((((2S,3S,5S)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-2,4,6-trimethyl-4-((((2S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2,3,4,5,6-pentamethyltetrahydro-2H-pyran-2-yl)methoxy)methyl)tetrahydro-2H-pyran-2-yl)methoxy)methyl)-3,4-dihydroxy-2,4,5,6,6-pentamethyltetrahydro-2H-pyran-2-yl 5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazxol-4-yl)pentanoate

50. (2S,5S)-3-acetamido-4-((((2R,5S)-5-((((2R,5S)-4,5-dihydroxy-6-(hydroxymethyl)-2,3,4,5,6-pentamethyl-3-((((2S,5S)-3,4,5-trihydroxy-2,3,4,5,6,6-hexamethyltetrahydro-2H-pyran-2-yl)methoxy)methyl)tetrahydro-2H-pyran-2-yl)methoxy)methyl)-3,4-dihydroxy-2, 3,4,5,6,6-hexamethyltetrahydro-2H-pyran-2-yl)methoxy)methyl)-5-hydroxy-6-(hydroxymethyl)-2,3,4,5,6-pentamethyltetrahydro-2H-pyran-2-yl 5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate

Structures of iminobiotin compounds are not shown in Table 2. However, the iminobiotin structures are analogs of the biotin structure where the biotin group is replaced by an iminobiotin group. An example is shown below.

In an embodiment of the invention, metal derived targeting agents may be polymeric or monomeric. Polymeric metal derived targeting agents are fully described in U.S. Pat. No. 7,169,410. Monomeric metal derived targeting agents are described in U.S. Pat. No. 4,603,044. Whether polymeric or monomeric, the compounds generally comprise a metal (typically purchased as an inorganic salt) that may be selected from the transition and inner transition metals or neighbors of the transition metals. The transition and inner transition metals from which the metal is selected include: Sc (scandium), Y (yttrium), La (lanthanum), Ac (actinium), the actinide series; Ti (titanium), Zr (zirconium), Hf (hafnium), V (vanadium), Nb (niobium), Ta (tantalum), Cr (chromium), Mo (molybdenum), W (tungsten), Mn (manganese), Tc (technetium), Re (rhenium), Fe (iron), Co (cobalt), Ni (nickel), Ru (ruthenium), Rh (rhodium), Pd (palladium), Os (osmium), Ir (iridium), and Pt (platinum). The neighbors of the transition metals from which the metal may be selected are: Cu (copper), Ag (silver), Au (gold), Zn (zinc), Cd (cadmium), Hg (mercury), Al (aluminum), Ga (gallium), In (indium), Tl (thallium), Ge (germanium), Sn (tin), Pb (lead), Sb (antimony) and Bi (bismuth), and Po (polonium). Preferably, the metal is chromium.

Non-limiting examples of useful salts include chromium chloride (III) hexahydrate; chromium (III) fluoride tetrahydrate; chromium (III) bromide hexahydrate; zirconium (IV) citrate ammonium complex; zirconium (IV) chloride; zirconium (IV) fluoride hydrate; zirconium (IV) iodide; molybdenum (III) bromide; molybdenum (III) chloride; molybdenum (IV) sulfide; iron (III) hydrate; iron (III) phosphate tetrahydrate, iron (III) sulfate pentahydrate, and the like.

In addition to a metal, the metal derived targeting agent comprises one or more complexing agents. A complexing agent is a compound capable of forming a water insoluble coordination complex with the preferred metal. There are several families of suitable complexing agents.

A complexing agent may be selected from the family of iminodiacetic acids of formula (1) wherein R₁is loweralkyl, aryl, arylloweralkyl, or a heterocyclic substituent.

Suitable compounds of formula (1) include:

N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2,6-diethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2,6-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(4-isopropylphenylcarbamoylmethyl)iminodiacetic acid;
N-(4-butylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2,3-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2,4-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2,5-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(3,4-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(3,5-dimethylphenylcarbamoylmethyl)iminodiacetic acid;
N-(3-butylphenylcarbamoylmethyl)iminodiacetic acid;
N-(2-butylphenylcarbamoylmethyl)iminodiacetic acid;
N-(4-tertiary butylphenylcarbamoylmethyl)iminodiacetic acid;
N-(3-butoxyphenylcarbamoylmethyl)iminodiacetic acid;
N-(2-hexyloxyphenylcarbamoylmethyl)iminodiacetic acid;
N-(4-hexyloxyphenylcarbamoylmethyl)iminodiacetic acid;
Aminopyrrol iminodiacetic acid;
N-(3-bromo-2,4,6-trimethylphenylcarbamoylmethyl)iminodiacetic acid;
Benzimidazole methyl iminodiacetic acid;
N-(3-cyano-4,5-dimethyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid;
N-(3-cyano-4-methyl-5-benzyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid; and
N-(3-cyano-4-methyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid and other derivatives of N-(3-cyano-4-methyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid of formula (2),

wherein R₂and R₃are the following:

R₂ R₃ H iso-C₄H₉ H CH₂CH₂SCH₃ H CH₂C₆H₄-p-OH CH₃ CH₃ CH₃ iso-C₄H₉ CH₃ CH₂CH₂SCH₃ CH₃ C₆H₅ CH₃ CH₂C₆H₅ CH₃ CH₂C₆H₄-p-OCH₃

Alternatively, the complexing agent may be selected from the family of imino diacid derivatives of formula (3), wherein R₄, R₅, and R₆are independently selected at each occurrence and may be hydrogen, loweralkyl, aryl, arylloweralkyl, alkoxyloweralkyl, and heterocyclic.

Suitable compounds of formula (3) include: N′-(2-acetylnaphthyl)iminodiacetic acid (NAIDA); N′-(2-naphthylmethyl)iminodiacetic acid (NMIDA); iminodicarboxymethyl-2-naphthylketone phthalein complexone; 3 (3: 7a: 12a: trihydroxy-24-norchol anyl-23-iminodiacetic acid; benzimidazole methyl iminodiacetic acid; and N-(5,pregnene-3-p-ol-2-oyl carbamoylmethyl)iminodiacetic acid.

The complexing agent may also be selected from the family of amino acids of formula (4),

where R₇is an amino acid side chain; wherein R₈may be loweralkyl, aryl, and arylloweralkyl; and wherein R₉is pyridoxylidene.

Suitable amino acids of the formula (4) are aliphatic amino acids, including, but not limited to: glycine, alanine, valine, leucine, isoleucine; hydroxyamino acids, including serine, and threonine; dicarboxylic amino acids and their amides, including aspartic acid, asparagine, glutamic acid, glutamine; amino acids having basic functions, including lysine, hydroxylysine, histidine, arginine; aromatic amino acids, including phenylalanine, tyrosine, tryptophan, thyroxine; and sulfur-containing amino acids, including cystine and methionine.

The complexing agent may also be selected from amino acid derivatives including, but not limited to (3-alanine-y-amino) butyric acid, O-diazoacetylserine (azaserine), homoserine, ornithine, citrulline, penicillamine and members of the pyridoxylidene class of compounds. Pyridoxylidene compounds include, but are not limited to: pyridoxylidene glutamate; pyridoxylidene isoleucine; pyridoxylidene phenylalanine; pyridoxylidene tryptophan; pyridoxylidene-5-methyl tryptophan; pyridoxylidene-5-hydroxytryptamine; and pyridoxylidene-5-butyltryptamine.

The complexing agent may likewise be selected from the family of diamines of formula (6):

wherein R₁₀is hydrogen, loweralkyl, or aryl; R₁₁is loweralkylene or arylloweralky; R₁₂and R₁₃are independently selected at each occurrence and may be hydrogen, loweralkyl, alkyl, aryl, arylloweralkyl, acylheterocyclic, toluene, sulfonyl or tosylate.

Examples of suitable diamines of formula (6) include, but are not limited to, ethylenediamine-N,N diacetic acid; ethylenediamine-N,N-bis(-2-hydroxy-5-bromophenyl)acetate; N′-acetylethylenediamine-N,N diacetic acid; N′-benzoyl ethylenediamine-N,N diacetic acid; N′-(p-toluenesulfonyl)ethylenediamine-N,N diacetic acid; N′-(p-t-butylbenzoyl)ethylenediamine-N,N diacetic acid; N′-(benzenesulfonyl)ethylenediamine-N,N diacetic acid; N′-(p-chlorobenzenesulfonyl)ethylenediamine-N,N diacetic acid; N′-(p-ethylbenzenesulfonyl ethylenediamine-N,N diacetic acid; N′-acyl and N′-sulfonyl ethylenediamine-N,N diacetic acid; N′-(p-n-propylbenzenesulfonyl)ethylenediamine-N,N diacetic acid; N′-(naphthalene-2-sulfonyl)ethylenediamine-N,N diacetic acid; and N′-(2,5-dimethylbenzenesulfonyl)ethylenediamine-N,N diacetic acid.

Other, non-limiting examples of complexing compounds or agents include penicillamine; p-mercaptoisobutyric acid; dihydrothioctic acid; 6-mercaptopurine; kethoxal-bis(thiosemicarbazone); Hepatobiliary Amine Complexes, 1-hydrazinophthalazine(hydralazine); sulfonyl urea; Hepatobiliary Amino Acid Schiff Base Complexes; pyridoxylidene glutamate; pyridoxylidene isoleucine; pyridoxylidene phenylalanine; pyridoxylidene tryptophan; pyridoxylidene 5-methyl tryptophan; pyridoxylidene-5-hydroxytryptamine; pyridoxylidene-5-butyltryptamine; tetracycline; 7-carboxy-p-hydroxyquinoline; phenolphthalein; eosin I bluish; eosin I yellowish; verograffin; 3-hydroxyl-4-formyl-pyridene glutamic acid; Azo substituted iminodiacetic acid; hepatobiliary dye complexes, such as rose bengal; congo red; bromosulfophthalein; bromophenol blue; toluidine blue; and indocyanine green; hepatobiliary contrast agents, such as iodipamide; and ioglycamic acid; bile salts, such as bilirubin; cholgycyliodohistamine; and thyroxine; hepatobiliary thio complexes, such as penicillamine; p-mercaptoisobutyric acid; dihydrothiocytic acid; 6-mercaptopurine; and kethoxal-bis(thiosemicarbazone); hepatobiliary amine complexes, such as 1-hydrazinophthalazine(hydralazine); and sulfonyl urea; hepatobiliary amino acid Schiff Base complexes, including pyridoxylidene-5-hydroxytryptamine; and pyridoxylidene-5-butyltryptamine; hepatobiliary protein complexes, such as protamine; ferritin; and asialo-orosomucoid; and asialo complexes, such as lactosaminated albumin; immunoglobulins, G, IgG; and hemoglobin.

Non-Covalent Association of Therapeutic and Diagnostic Agents

As noted previously, in certain embodiments, one or more therapeutic agents may be associated with the composition of the present invention. Examples of therapeutic agents include, but are not limited to, insulin, interferon, rituximab, trastuzumab, uricase, tissue plasminogen activator, thymoglobin, various vaccines, heparin, heparin analogs, antithrombin III, filgrastin, pramilitide acetate, exanatide, epifibatide, antivenins, IgG, IgM, blood clotting Factors VII, VIII, IX, Kallikrein, Kininogen, Hageman Factor (XII), plasma thromboplastin antecedent Factor (XI), tissue factor, Stuart Factor (X), accelerin (V), prothrombin (II), and fibrin stabilizing Factor (XIII); HGH, GLP-1, erythropoietin, parathyroid hormone, serotonin, D- or L-thyroxine, calcitonin, monoclonal antibodies, as well as other therapeutic agents that may include, but are not limited to:

- 12AP1/E5—Viventia Biotech
- 1964—Aventis
- 20K growth hormone—AMUR
- 28P6/E6—Viventia Biotech
- 3-Hydroxyphthaloyl-beta-lactoglobulin
- 4-IBB ligand gene therapy
- 64-Cu MAb conjugate TETA-1A3—Mallinckrodt Institute of Radiology
- 64-Cu MAb conjugate TETA-cT84.66
- 64-Cu Trastuzumab TETA conjugate—Genentech
- A 200—Amgen
- A10255—Eli Lilly
- A1PDX—Hedral Therapeutics
- A6—Angstrom
- aaAT-III—Genzyme
- Abciximab—Centocor
- ABI.001—Atlantic BioPharmaceuticals
- ABT-828—Abbott
- Accutin
- Actinohivin
- activin—Biotech Australia, Human Therapeutics, Curis
- AD 439—Tanox
- AD 519—Tanox
- Adalimumab—Cambridge Antibody Tech.
- Adenocarcinoma vaccine—Biomira—NIS
- Adenosine deanimase Enzond
- Adenosine A2B receptor antagonists—Adenosine Therapeutics
- ADP-001 Axis Genetics
- AF 13948 Affymax
- Afelimomab—Knoll
- AFP-SCAN—Immunomedics
- AG 2195—Corixa
- agalsidase alfa—Transkaryotic Therapies
- agalsidase beta—Genzyme
- AGENT—Antisoma
- AI 300—AutoImmune
- AI-101—Teva
- AI-102—Teva
- AI-201 AutoImmune
- AI-301 AutoImmune
- AIDS vaccine—ANRS, CIBG, Hesed Biomed, Hollis-Eden, Rome, United Biomedical, American Home Products, Maxygen
- airway receptor ligand—IC Innovations
- AJvW 2—Ajinomoto
- AK 30 NGF Alkermes
- Albuferon—Human Genome Sciences
- albumin—Biogen, DSM Anti-Infectives, Genzyme Transgenics, PPL Therapeutics,
- TranXenoGen, Welfide Corp.
- aldesleukin—Chiron
- alefacept—Biogen
- Alemtuzumab
- Allergy therapy—ALK-Abello/Maxygen, ALK-Abello/RP Scherer
- allergy vaccines—Allergy Therapeutics
- Alnidofibatide—Aventis Pasteur
- Alnorine—SRC VB VECTO
- ALP 242—Gruenentha
- Alpha antitrypsin Arriva/Hyland Immuno/ProMetic/Protease Sciences
- Alpha-1 antitrypsin—Cutter, Bayer, PPL Therapeutics, Profile, ZymoGenetics, Arriva
- Alpha-1 protease inhibitor—Genzyme Transgenics, Welfide Corp.
- Alpha-galactose fusion protein—Immunomedics
- Alpha-galactosidase A—Research Corporation Technologies, Genzyme
- Alpha-glucosidase Genzyme, Novazyme
- Alpha-lactalbumin
- Alpha-L-iduronidase—Transkaryotic Therapies, BioMarin
- alteplase—Genentech
- alvircept sudotox—NIH
- ALX1-11—sNPS Pharmaceuticals
- Alzheimer's disease gene therapy
- AM-133—AMRAD
- Amb a 1 immunostim conj.—Dynavax
- AMD 3100—AnorMED—NIS
- AMD 3465—AnorMED—NIS
- AMD 3465—AnorMED—NIS
- AMD Fab—Genentech
- Amediplase—Menarini, Novartis
- AMD Fab—Genentech
- Amediplase—Menarini, Novartis
- AM-F9
- Amoebiasis vaccine
- Amphiregulin—Octagene
- anakinra—Amgen
- analgesic—Nobex
- ancestim—Amgen
- AnergiX.RA—Corixa, Organon
- Angiocidin—InKine
- angiogenesis inhibitors—ILEX
- AngioMab—Antisoma
- Angiopoietins Regeneron/Procter & Gamble
- angiostatin—EntreMed
- Angiostatin/endostatin gene therapy—Genetix Pharmaceuticals
- angiotensin-II, topical—Maret
- Anthrax—EluSys Therapeutics/US Army Medical Research Institute
- Anthrax vaccine
- Anti platelet-derived growth factor D human monoclonal antibodies—CuraGen
- Anti-17-1A MAb 3622W94—GlaxoSmithKline
- Anti-2C4 MAb—Genentech
- anti-4-1BB monoclonal antibodies—Bristol-Myers Squibb
- Anti-Adhesion Platform Tech.—Cytovax
- Anti-adipocyte MAb—Cambridge Antibody Tech./ObeSys
- antiallergics—Maxygen
- antiallergy vaccine—Acambis
- Anti-alpha-4-integrin MAb
- Anti-alphavβ3 integrin MAb—Applied Molecular Evolution
- Anti-angiogenesis monoclonal antibodies—KS Biomedix/Schering AG
- Anti-B4 MAb-DC1 conjugate—ImmunoGen
- Anti-B7 antibody PRIMATIZED—IDEC
- Anti-B7-1 MAb 16-10A1
- Anti-B7-1 MAb 1G10
- Anti-B7-2 MAb GL-1
- Anti-B7-2-gelonin immunotoxin
- Antibacterials/antifungals—Diversa/IntraBiotics
- Anti-beta-amyloid monoclonal antibodies—Cambridge Antibody Tech., Wyeth-Ayerst
- Anti-BLyS antibodies—Cambridge Antibody Tech./Human Genome Sciences
- Antibody-drug conjugates—Seattle Genetics/Eos
- Anti-C5 MAb BB5-1—Alexion
- Anti-C5 MAb N19-8—Alexion
- Anti-C8 MAb
- anticancer cytokines—BioPulse
- anticancer matrix—Telios Integra
- Anticancer monoclonal antibodies—ARIUS, Immunex
- anticancer peptides—Maxygen, Micrologix
- Anticancer prodrug Tech.—Alexion Antibody Technologies
- Anticancer Troy-Bodies—Affite—Affitech
- anticancer vaccine—NIH
- anticancers—Epimmune
- Anti-CCR5/CXCR4 sheep MAb—KS Biomedix Holdings
- Anti-CD11a MAb KBA
- Anti-CD11a MAb M17
- Anti-CD11a MAb TA-3
- Anti-CD11a MAb WT.1
- Anti-CD11b MAb—Pharmacia
- Anti-CD11b MAb LM2
- Anti-CD154 MAb—Biogen
- Anti-CD16-anti-CD30 MAb—Biotest
- Anti-CD18 MAb—Pharmacia Anti-CD19 MAb B43
- Anti-CD19 MAb—liposomal sodium butyrate conjugate
- Anti-CD147
- Anti-CD19 MAb-saporin conjugate
- Anti-CD 19-dsFv-PE38-immunotoxin
- Anti-CD2 MAb 12-15
- Anti-CD2 MAb B-E2 Diaclone
- Anti-CD2 MAb OX34
- Anti-CD2 MAb OX54
- Anti-CD2 MAb OX55
- Anti-CD2 MAb RM2-1
- Anti-CD2 MAb RM2-2
- Anti-CD2 MAb RM2-4
- Anti-CD20 MAb BCA B20
- Anti-CD20-anti-Fc alpha RI bispecific MAb—Medarex, Tenovus
- Anti-CD22 MAb-saporin-6 comple
- Anti-CD3 immunotoxi
- Anti-CD3 MAb 145-2C11—Pharming
- Anti-CD3 MAb CD4IgG conjugate—Genentech
- Anti-CD3 MAb humanised—Protein Design, RW Johnson
- Anti-CD3 MAb WT32
- Anti-CD3 MAb-ricin-chain-A conjugate
- Anti-CD3 MAb-xanthirie-oxidase conjugate
- Anti-CD30 MAb BerH2—Medac
- Anti-CD30 MAb-saporin conjugate
- Anti-CD30-scFv-ETA′-immunotoxin
- Anti-CD38 MAb AT13/5
- Anti-CD38 MAb-saporin conjugate
- Anti-CD3-anti-CD19 bispecific MAb
- Anti-CD3-anti-EGFR MAb
- Anti-CD3-anti-interleukin-2-receptor MAb
- Anti-CD3-anti-MOv18 MAb—Centocor
- Anti-CD3-anti-SCLC bispecific MAb
- Anti-CD4 idiotype vaccine
- Anti-CD4 MAb Centocor, IDEC Pharmaceuticals, Xenova Group
- Anti-CD4 MAb 16H5
- Anti-CD4 MAb 4162W94 GlaxoSmithKline
- Anti-CD4 MAb B-F5—Diaclone
- Anti-CD4 MAb GK1-5
- Anti-CD4 MAb KT6
- Anti-CD4 MAb OX38
- Anti-CD4 MAb PAP conjugate—Bristol-Myers Squibb
- Anti-CD4 MAb RIB 5-2
- Anti-CD4 MAb W3/25
- Anti-CD4 MAb YTA 3.1.2
- Anti-CD4 MAb YTS 177-9
- Anti-CD40 ligand MAb 5c8—Biogen
- Anti-CD40 MAb
- Anti-CD40 MAb 5D 12—Tanox
- Anti-CD44 MAb A3D8
- Anti-CD44 MAb GKWA3
- Anti-CD44 MAb IM7
- Anti-CD44 MAb KM81
- Anti-CD44 variant monoclonal antibodies—Corixa/Hebrew University
- Anti-CD45 MAb BC8-I-131
- Anti-CD45RB MAb
- Anti-CD48 MAb HuLy-m3
- Anti-CD48 MAb WM-63
- Anti-CD5 MAb—Becton Dickinson
- Anti-CD5 MAb OX19
- Anti-CD6 MAb
- Anti-CD7 MAb-PAP conjugate
- Anti-CD7 MAb-ricin-chain-A conjugate
- Anti-CD8 MAb Amerimmune, Cytodyn, Becton Dickinson
- Anti-CD8 MAb 2-43
- Anti-CD8 MAb OX8
- Anti-CD80 MAb P16C10 IDEC
- Anti-CD80 MAb P7C10—ID Vaccine
- Anti-CD8-idarubicin conjugate
- Anti-CEA MAb CE-25
- Anti-CEA MAb MN14—Immunomedics
- Anti-CEA MAb MN14-PE40 conjugate—Immunomedics
- Anti-CEA MAb T84.66-interleukin-2 conjugate
- Anti-CEA sheep MAb—KS Biomedix Holdings
- Anti-cell surface monoclonal antibodies—Cambridge Antibody Tech./Pharmacia
- Anti-c-erbB2-anti-CD3 bifunctional MAb—Otsuka
- Anti-CMV MAb—Scotgen
- Anti-complement
- Anti-CTLA-4 MAb
- Anti-EGFR catalytic antibody—Hesed Biomed
- anti-EGFR immunotoxin—IVAX
- Anti-EGFR MAb—Abgenix
- Anti-EGFR MAb 528
- Anti-EGFR MAb KSB 107—KS Biomedix
- Anti-EGFR MAb-DM1 conjugate—ImmunoGen
- Anti-EGFR MAb-LA1
- Anti-EGFR sheep MAb—KS Biomedix
- Anti-FAP MAb F19-1-131
- Anti-Fas IgM MAb CH11
- Anti-Fas MAb Jo2
- Anti-Fas MAb RK-8
- Anti-Flt-1 monoclonal antibodies—ImClone
- Anti-fungal peptides—State University of New York
- antifungal tripeptides—BTG
- Anti-ganglioside GD2 antibody-interleukin-2 fusion protein—Lexigen
- Anti-GM2 MAb—Kyowa
- Anti-GM-CSF receptor monoclonal antibodies—AMRAD
- Anti-gp130 MAb—Tosoh
- Anti-HCA monoclonal antibodies—AltaRex/Epigen
- Anti-hCG antibodies—Abgenix/AVI BioPharma
- Anti-heparanase human monoclonal antibodies—Oxford Glycosciences/Medarex
- Anti-hepatitis C virus human monoclonal antibodies—XTL Biopharmaceuticals
- Anti-HER-2 antibody gene therapy
- Anti-herpes antibody—Epicyte
- Anti-HIV antibody—Epicyte
- anti-HIV catalytic antibody—Hesed Biomed
- anti-HIV fusion protein—Idun
- anti-HIV proteins—Cangene
- Anti-HM1-24 MAb—Chugai
- Anti-hR3 MAb
- Anti-Human-Carcinoma-Antigen MAb—Epicyte
- Anti-ICAM-1 MAb Boehringer Ingelheim
- Anti-ICAM-1 1A-29—Pharmacia
- Anti-ICAM-1 MAb HA58
- Anti-ICAM-1 MAb YN1/1.7.4
- Anti-ICAM-3 MAb ICM3—ICOS
- Anti-idiotype breast cancer vaccine 11D10
- Anti-idiotype breast cancer vaccine ACA14C5
- Anti-idiotype cancer vaccine—ImClone Systems/Merck KGaA ImClone, Viventia Biotech
- Anti-idiotype cancer vaccine 1A7—Titan
- Anti-idiotype cancer vaccine 3H1—Titan
- Anti-idiotype cancer vaccine TriAb—Titan
- Anti-idiotype Chlamydia trachomatis vaccine
- Anti-idiotype colorectal cancer vaccine—Novartis
- Anti-idiotype colorectal cancer vaccine—Onyvax
- Anti-idiotype melanoma vaccine—IDEC Pharmaceuticals
- Anti-idiotype ovarian cancer vaccine ACA 125
- Anti-idiotype ovarian cancer vaccine AR54—AltaRex
- Anti-idiotype ovarian cancer vaccine CA-125—AltaRex, Biomira
- Anti-IgE catalytic antibody—Hesed Biomed
- Anti-IgE MAb E26—Genentech
- Anti-IGF-1 MAb
- anti-inflammatory—GeneMax
- anti-inflammatory peptide—BTG
- anti-integrin peptides—Burnha
- Anti-interferon-alpha-receptor MAb 64G12—Pharma Pacific Management
- Anti-interferon-gamma MAb—Protein Design Labs
- Anti-interferon-gamma polyclonal antibody—Advanced Biotherapy
- Anti-interleukin-10 MAb
- Anti-interleukin-12 MAb
- Anti-interleukin-1-beta polyclonal antibody—R&D Systems
- Anti-interleukin-2 receptor MAb 2A3
- Anti-interleukin-2 receptor MAb 33B3-1—Immunotech
- Anti-interleukin-2 receptor MAb ART-18
- Anti-interleukin-2 receptor MAb LO-Tact-1
- Anti-interleukin-2 receptor MAb Mikbeta1
- Anti-interleukin-2 receptor MAb NDS61
- Anti-interleukin-4 MAb 11B11
- Anti-interleukin-5 MAb—Wallace Laboratories
- Anti-interleukin-6 MAb—Centocor, Diaclone, Pharmadigm
- Anti-interleukin-8 MAb—Abgenix
- Anti-interleukin-8 MAb—Xenotech
- Anti-JL1 MAb
- Anti-Klebsiella sheep MAb—KS Biomedix Holdings
- Anti-Laminin receptor MAb-liposomal doxorubicin conjugate
- Anti-LCG MAb—Cytoclonal
- Anti-lipopolysaccharide MAb—VitaResc
- Anti-L-selectin monoclonal antibodies—Protein Design Labs, Abgenix, Stanford University
- Anti-MBL monoclonal antibodies—Alexion/Brigham and Women's Hospital
- Anti-MHC monoclonal antibodies
- Anti-MIF antibody humanised—IDEC, Cytokine PharmaSciences
- Anti-MRSA/VRSA sheep MAb—KS Biomedix Holdings
- Anti-mu MAb—Novartis
- Anti-MUC-1 MAb
- Anti-MUC 18
- Anti-Nogo-A MAb IN1
- Anti-nuclear autoantibodies—Procyon
- Anti-ovarian cancer monoclonal antibodies—Dompe
- Anti-p185 monoclonal antibodies
- Anti-p43 MAb
- Antiparasitic vaccines
- Anti-PDGF/bFGF sheep MAb—KS Biomedix
- Anti-properdin monoclonal antibodies—Abgenix/Gliatech
- Anti-PSMA (prostrate specific membrane antigen)
- Anti-PSMA MAb J591—BZL Biologics
- Anti-Rev MAb gene therapy
- Anti-RSV antibodies—Epicyte, Intracell
- Anti-RSV monoclonal antibodies—Medarex/MedImmune, Applied Molecular
- Evolution/MedImmune
- Anti-RSV MAb, inhalation—Alkermes/MedImmune
- Anti-RT gene therapy
- Antisense K-ras RNA gene therapy
- Anti-SF-25 MAb
- Anti-sperm antibody—Epicyte
- Anti-Tac(Fv)-PE38 conjugate
- Anti-TAPA/CD81 MAb AMP1
- Anti-tat gene therapy
- Anti-TCR-alphabeta MAb H57-597
- Anti-TCR-alphabeta MAb R73
- Anti-tenascin MAb BC-4-I-131
- Anti-TGF-beta human monoclonal antibodies—Cambridge Antibody Tech., Genzyme
- Anti-TGF-beta MAb 2G7—Genentech
- Antithrombin III—Genzyme Transgenics, Aventis, Bayer, Behringwerke, CSL, Myriad
- Anti-Thy1 MAb
- Anti-Thy1.1 MAb
- Anti-tissue factor/factor VIIA sheep MAb—KS Biomedix
- Anti-TNF monoclonal antibodies—Centocor, Chiron, Peptech, Pharacia, Serono
- Anti-TNF sheep MAb—KS Biomedix Holdings
- Anti-TNFalpha MAb—Genzyme
- Anti-TNFalpha MAb B-C7—Diaclone
- Anti-tooth decay MAb—Planet BioTech.
- Anti-TRAIL receptor-1 MAb—Takeda
- Antitumour RNases—NIH
- Anti-VCAM MAb 2A2—Alexion
- Anti-VCAM MAb 3F4—Alexion
- Anti-VCAM-1 MAb
- Anti-VEC MAb—ImClone
- Anti-VEGF MAb—Genentech
- Anti-VEGF MAb 2C3
- Anti-VEGF sheep MAb—KS Biomedix Holdings
- Anti-VLA-4 MAb HP 1/2—Biogen
- Anti-VLA-4 MAb PS/2
- Anti-VLA-4 MAb R1-2
- Anti-VLA-4 MAb TA-2
- Anti-VAP-1 human MAb
- Anti-VRE sheep MAb—KS Biomedix Holdings
- ANUP—TranXenoGen
- ANUP-1—Pharis
- AOP-RANTES—Senetek
- Apan-CH—Praecis Pharmaceuticals
- APC-8024—Demegen
- ApoA-1—Milano, Pharmacia
- Apogen—Alexion
- apolipoprotein A1—Avanir
- Apolipoprotein E—Bio-Tech. General
- Applaggin—Biogen
- aprotinin—ProdiGene
- APT-070C—AdProTech
- AR 177—Aronex Pharmaceuticals
- AR 209—Aronex Pharmaceuticals, Antigenics
- ARGENT gene delivery systems—ARIAD
- Arresten
- ART-123 Asahi Kasei
- arylsulfatase B—BioMarin
- Arylsulfatase B, Recombinant human—BioMarin
- AS 1051—Ajinomoto
- ASI-BCL—Intracell
- Asparaginase—Merck
- ATL-101—Alizyme
- Atrial natriuretic peptide—Pharis
- Aurintricarboxylic acid-high molecular weight
- Autoimmune disorders—GPC Biotech/MorphoSys
- Autoimmune disorders and transplant rejection—Bristol-Myers Squibb/Genzyme Tra
- Autoimmune disorders/cancer—Abgenix/Chiron, CuraGen
- Autotaxin
- Avicidin—NeoRx
- axogenesis factor-1—Boston Life Sciences
- Axokine—Regeneron
- B cell lymphoma vaccine—Biomira
- B7-1 gene therapy
- BABS proteins—Chiron
- BAM-002—Novelos Therapeutics
- Basiliximab (anti CD25 MAb)—Novartis
- Bay-16-9996—Bayer
- Bay-39-9437—Bayer
- Bay-50-4798—Bayer
- BB-10153—British Biotech
- BBT-001—Bolder BioTech.
- BBT-002—Bolder BioTech.
- BBT-003—Bolder BioTech.
- BBT-004—Bolder BioTech.
- BBT-005—Bolder BioTech.
- BBT-006—Bolder BioTech.
- BBT-007—Bolder BioTech.
- BCH-2763—Shire
- BCSF—Millenium Biologix
- BDNF—Regeneron—Amgen
- Becaplermin—Johnson & Johnson, Chiron
- Bectumomab—Immunomedics
- Beriplast—Aventis
- Beta-adrenergic receptor gene therapy—University of Arkansas
- bFGF—Scios
- BI 51013—Behringwerke AG
- BIBH 1—Boehringer Ingelheim
- BIM-23190—Beaufour-Ipsen
- birch pollen immunotherapy—Pharmacia
- bispecific fusion proteins—NIH
- Bispecific MAb 2B1—Chiron
- Bitistatin
- BIWA 4—Boehringer Ingelheim
- blood substitute—Northfield, Baxter Intl.
- BLP-25—Biomira
- BLS-0597—Boston Life Sciences
- BLyS—Human Genome Sciences
- BLyS radiolabelled—Human Genome Sciences
- BM 06021—Boehringer Mannheim
- BM-202—BioMarin
- BM-301—BioMarin
- BM-301—BioMarin
- BM-302—BioMarin
- BMP 2—Genetics Institute/Medtronic-Sofamor Danek, Genetics Institute/Collagenesis, Genetics Institute/Yamanouch
- BMP 2 gene therapy
- BMP 52—Aventis Pasteur, Biopharm
- BMP-2—Genetics Institute
- BMS 182248—Bristol-Myers Squibb
- BMS 202448—Bristol-Myers Squibb
- bone growth factors—IsoTis
- BPC-15—Pfizer
- brain natriuretic peptide
- Breast cancer—Oxford GlycoSciences/Medarex
- Breast cancer vaccine—Therion Biologics, Oregon
- BSSL—PPL Therapeutics
- BST-2001—BioStratum
- BST-3002—BioStratum
- BTI 322
- butyrylcholinesterase—Shire
- C 6822—COR Therapeutics
- C1 esterase inhibitor—Pharming
- C3d adjuvant AdProTech
- CAB-2.1—Millennium
- calcitonin—Inhale Therapeutics Systems, Aventis, Genetronics, TranXenoGen, Unigene, Rhone Poulenc Rohrer
- calcitonin—oral—Nobex, Emisphere, Pharmaceutical Discovery
- Calcitonin gene-related peptide—Asahi Kasei—Unigene
- calcitonin, human—Suntory
- calcitonin, nasal—Novartis, Unigene
- calcitonin, Panoderm—Elan
- calcitonin, Peptitrol—Shire
- calcitonin, salmon—Therapicon
- calin—Biopharm
- Calphobindin I
- calphobindin I—Kowa
- calreticulin—NYU
- Campath-1G
- Campath-1M
- cancer therapy—Cangene
- cancer vaccine—Aixlie, Aventis Pasteur, Center of Molecular Immunology, YM BioSciences, Cytos, Genzyme, Transgenics, GlobeImmune, Igeneon, ImClone, Virogenetics, InterCell, Iomai, Jenner Biotherapies, Memorial Sloan-Kettering Cancer Center, Sydney Kimmel Cancer Center, Novavax, Protein Sciences, Argonex, SIGA
- Cancer vaccine ALVAC-CEA B7.1—Aventis Pasteur/Therion Biologics
- Cancer vaccine CEA-TRICOM—Aventis Pasteur/Therion Biologics
- Cancer vaccine gene therapy—Cantab Pharmaceuticals
- Cancer vaccine HER-2/neu—Corixa
- Cancer vaccine THERATOPE—Biomira
- cancer vaccine, PolyMASC—Valentis
- Candida vaccine—Corixa, Inhibitex
- Canstatin—ILEX
- CAP-18—Panorama
- Cardiovascular gene therapy—Collateral Therapeutics
- carperitide—Suntory
- Casocidin-1—Pharis
- CAT 152—Cambridge Antibody Tech.
- CAT 192—Cambridge Antibody Tech.
- CAT 213—Cambridge Antibody Tech.
- Catalase—Enzon
- Cat-PAD—Circassia
- CB 0006—Celltech
- CCK(27-32)—Akzo Nobel
- CCR2-64I—NIH
- CD, Procept—Paligent
- CD154 gene therapy
- CD39—Immunex
- CD39-L2—Hyseq
- CD39-L4—Hyseq
- CD4 fusion toxin—Senetek
- CD4 IgG—Genentech
- CD4 receptor antagonists—Pharmacopeia/Progenics
- CD4 soluble—Progenics
- CD4, soluble—Genzyme Transgenics
- CD40 ligand—Immunex
- CD4-ricin chain A—Genentech
- CD59 gene therapy—Alexion
- CD8 TIL cell therapy—Aventis Pasteur
- CD8, soluble—Avidex
- CD95 ligand—Roche
- CDP 571—Celltech
- CDP 850—Celltech
- CDP-860 (PEG-PDGF MAb)—Celltech
- CDP 870—Celltech
- CDS-1—Ernest Orlando
- Cedelizumab—Ortho-McNeil
- Cetermin—Insmed
- CETP vaccine—Avant
- Cetrorelix
- Cetuximab
- CGH 400—Novartis
- CGP 42934—Novartis
- CGP 51901—Tanox
- CGRP—Unigene
- CGS 27913—Novartis
- CGS 32359—Novartis
- Chagas disease vaccine—Corixa
- chemokines—Immune Response
- CHH 380—Novartis
- chitinase—Genzyme, ICOS
- Chlamydia pneumoniae vaccine—Antex Biologics
- Chlamydia trachomatis vaccine—Antex Biologics
- Chlamydia vaccine—GlaxoSmithKline
- Cholera vaccine CVD 103-HgR—Swiss Serum and Vaccine Institute Berne
- Cholera vaccine CVD 112—Swiss Serum and Vaccine Institute Berne
- Cholera vaccine inactivated oral—SBL Vaccin
- Chrysalin—Chrysalis BioTech.
- CI-782—Hitachi Kase
- Ciliary neurotrophic factor—Fidia, Roche
- CIM project—Active Biotech
- CL 329753—Wyeth-Ayerst
- CL22, Cobra—ML Laboratories
- Clenoliximab IDEC
- Clostridium difficile antibodies—Epicyte
- clotting factors—Octagene
- CMB 401—Celltech
- CNTF—Sigma-Tau
- Cocaine abuse vaccine—Cantab, ImmuLogic, Scripps
- coccidiomycosis vaccine—Arizo
- collagen—Type I—Pharming
- Collagen formation inhibitors—FibroGen
- Collagen/hydroxyapatite/bone growth factor—Aventis Pasteur, Biopharm, Orquest
- collagenase—BioSpecifics
- Colorectal cancer vaccine—Wistar Institute
- Component B, Recombinant—Serono
- Connective tissue growth factor inhibitors—FibroGen/Taisho
- Contortrostatin
- contraceptive vaccine—Zonagen
- Contraceptive vaccine Hcg
- Contraceptive vaccine male reversible—IMMUCON
- Contraceptive vaccine zona pellucida—Zonagen
- Copper-64 labelled MAb TETA-1A3—NCI
- Coralyne
- Corsevin M
- C-peptide analogues—Schwarz
- CPI-1500—Consensus
- CRF—Neurobiological Tech.
- cRGDfV pentapeptide
- CRL 1095—CytRx
- CRL 1336—CytRx
- CRL 1605—CytRx
- CS-560—Sankyo
- CSF—ZymoGenetics
- CSF-G—Hangzhou, Dong-A, Hani
- CSF-GM—Cangene, Hunan, LG Chem
- CSF-M—Zarix
- CT 1579—Merck Frosst
- CT 1786—Merck Frosst
- CT-112̂—BTG
- CTB-134L—Xenova
- CTC-111—Kaketsuken
- CTGF—FibroGen
- CTLA4-Ig—Bristol-Myers Squibb
- CTLA4-Ig gene therapy
- CTP-37—AVI BioPharma
- C-type natriuretic peptide—Suntory
- CVS 995—Corvas Intl.
- CY 397—Nikko Kyodo
- CY 1747—Epimmune
- CY 1748—Epimmune
- Cyanovirin-N
- Cystic fibrosis therapy—CBR/IVAX
- CYT 351
- cytokine Traps—Regeneron
- cytokines—Enzon, Cytoclonal
- Cytomegalovirus glycoprotein vaccine—Chiron, Aquila Biopharmaceuticals, Aventis Pasteur, Virogenetics
- Cytomegalovirus vaccine live—Aventis Pasteur
- Cytosine deaminase gene therapy—GlaxoSmithKline
- DA-3003—Dong A
- DAB389interleukin-6—Senetek
- DAB389interleukin-7
- Daclizumab (anti-IL2R MAb)—Protein Design Labs
- DAMP̂—Incyte Genomics
- Daniplestim—Pharmacia
- darbepoetin alfa—Amgen
- DBI-3019—Diabetogen
- DCC—Genzyme
- DDF—Hyseq
- decorin—Integra, Telios
- defensins—Large Scale Biology
- DEGR-VIIa
- Deimmunised antibody 3B6/22 AGEN
- Deimmunised anti-cancer antibodies—Biovation/Viragen
- Dendroamide A
- Dengue vaccine—Bavarian Nordic, Merck
- denileukin diftitox—Ligand
- DES-1101—Desmos
- desirudin—Novartis
- desmopressin—Unigene
- Desmoteplase—Merck, Schering AG
- Destabilase
- Diabetes gene therapy—DeveloGen, Pfizer
- Diabetes therapy—Crucell
- Diabetes type 1 vaccine—Diamyd Therapeutics
- DiaCIM—YM BioSciences
- dialytic oligopeptides—Research Corp
- Diamyd—Diamyd Therapeutics
- DiaPep227—Pepgen
- DiavaX—Corixa
- Digoxin MAb—Glaxo
- Diphtheria tetanus pertussis-hepatitis B vaccine—GlaxoSmithKline
- DIR therapy—Solis Therapeutics
- DNase—Genentech
- Dornase alfa—Genentech
- Dornase alfa, inhalation—Genentech
- Doxorubicin-anti-CEA MAb conjugate—Immunomedics
- DP-107—Trimeris
- drotrecogin alfa—Eli Lilly
- DTctGMCSF
- DTP-polio vaccine—Aventis Pasteur
- DU 257-KM231 antibody conjugate—Kyowa
- dural graft matrix—Integra
- Duteplase—Baxter Intl.
- DWP-401—Daewoong
- DWP-404—Daewoong
- DWP-408—Daewoong
- Dx 88 (Epi-KAL2) Dyax
- Dx 890 (elastin inhibitors)—Dyax
- E coli 0157 vaccine—NIH
- E21-R—BresaGen
- Eastern equine encephalitis virus vaccine
- Echicetin
- Echinhibin 1
- Echistatin—Merck
- Echitamine
- Ecromeximab—Kyowa Hakko
- EC-SOD—PPL Therapeutics
- Eculizumab (5G1.1)—Alexion
- EDF—Ajinomoto
- EDN derivative—NIH
- EDNA—NIH
- Edobacomab XOMA
- Edrecolomab—Centocor
- EF 5077
- Efalizumab—Genentech
- EGF fusion toxin—Seragen, Ligand
- EGF-P64k vaccine—Center of Molecular Immunology
- EL 246—LigoCyte
- elastase inhibitor—Synergen
- elcatonin—Therapicon
- EMD 72000—Merck KGaA
- Emdogain—BIORA
- emfilermin—AMRAD
- Emoctakin—Novartis
- enamel matrix protein—BIORA
- Endo III—NYU
- endostatin—EntreMed, Pharis
- Enhancins—Micrologix
- Enlimomab—Isis Pharm.
- Enoxaparin sodium—Pharmuka
- enzyme linked antibody nutrient depletion therapy—KS Biomedix Holdings
- Eosinophil-derived neutralizing agent
- EP-51216—Asta Medica
- EP-51389—Asta Medica
- EPH family ligands—Regeneron
- Epidermal growth factor—Hitachi Kasei, Johnson & Johnson
- Epidermal growth factor fusion toxin—Senetek
- Epidermal growth factor-genistein
- EPI-HNE-4—Dyax
- EPI-KAL2—Dyax
- Epoetin-alfa—Amgen, Dragon Pharmaceuticals, Nanjing Huaxin
- Epratuzumab—Immunomedics
- Epstein-Barr virus vaccine—Aviron/SmithKline Beecham, Bioresearch
- Eptacog alfa—Novo Nordisk
- Eptifibatide—COR Therapeutics
- erb-38
- Erlizumab—Genentech
- erythropoietin—Alkermes, ProLease, Dong-A, Elanex, Genetics Institute, LG Chem, Protein Sciences, Serono, Snow Brand, SRC VB VECTOR, Transkaryotic Therapies
- Erythropoietin Beta—Hoffman La Roche
- Erythropoietin/Epoetin alfa—Chugai
- Escherichia coli vaccine—North American Vaccine, SBL Vaccin, Swiss Serum and Vaccine
- Institute Berne
- etanercept—Immunex
- examorelin—Mediolanum
- Exendin 4—Amylin
- exonuclease VII
- F 105—Centocor
- F-992—Fornix
- Factor IX—Alpha Therapeutics, Welfide Corp., CSL, enetics Institute/AHP, Pharmacia, PPL Therapeutics
- Factor IX gene therapy—Cell Genesys
- Factor VII—Novo Nordisk, Bayer, Baxter Intl.
- Factor VIIa—PPL Therapeutics, ZymoGenetics
- Factor VIII—Bayer Genentech, Beaufour-Ipsen, CLB, Inex, Octagen, Pharmacia, Pharming
- Factor VIII—PEGylated—Bayer
- Factor VIII fragments—Pharmacia
- Factor VIII gene therapy—Targeted Genetics
- Factor VIII sucrose formulation—Bayer, Genentech
- Factor VIII-2—Bayer
- Factor VIII-3—Bayer
- Factor Xa inhibitors—Merck, Novo Nordisk, Mochida
- Factor XIII—ZymoGenetics
- Factors VIII and IX gene therapy—Genetics Institute/Targeted Genetics
- Famoxin—Genset
- Fas (delta) TM protein—LXR BioTech.
- Fas TR—Human Genome Sciences
- Felvizumab—Scotgen
- FFR-VIIa—Novo Nordisk
- FG-001—F-Gene
- FG-002—F-Gene
- FG-004—F-Gene
- FG-005—F-Gene
- FGF+fibrin—Repair
- Fibrimage—Bio-Tech. General
- fibrin-binding peptides—ISIS Innovation
- fibrinogen—PPL Therapeutics, Pharming
- fibroblast growth factor—Chiron, NYU, Ramot, ZymoGenetics
- fibrolase conjugate—Schering AG
- Filgrastim—Amgen
- filgrastim—PDA modified—Xencor
- FLT-3 ligand—Immunex
- FN18 CRM
- follistatin—Biotech Australia, Human Therapeutics
- follitropin alfa—Alkermes, ProLease, PowderJect, Serono, Akzo Nobel
- Follitropin Beta—Bayer, Organon
- FP 59
- FSH—Ferring
- FSH+LH—Ferring
- F-spondin—CeNeS
- fusion protein delivery system—UAB Research Foundation
- fusion toxins—Boston Life Sciences
- G 5598—Genentech
- GA-II Transkaryotic Therapies
- Gamma-interferon analogues—SRC VB VECTOR
- Ganirelix—Roche
- gastric lipase—Meristem
- Gavilimomab
- G-CSF—Amgen, SRC VB VECTOR
- GDF-1—CeNeS
- GDF-5—Biopharm
- GDNF (glial derived neurotrophic factor)—Amgen
- gelsolin—Biogen
- Gemtuzumab ozogamicin—Celltech
- Gene-activated epoetin-alfa—Aventis Pharma—Transkaryotic Therapies
- Glanzmann thrombasthenia gene therapy
- Glatiramer acetate—Yeda
- glial growth factor 2—CeNeS
- GLP-1—Amylin, Suntory, TheraTech, Watson
- GLP-1 peptide analogues—Zealand Pharaceuticals
- glucagon—Eli Lilly, ZymoGenetics
- Glucagon-like peptide-1 7-36 amide—Suntory
- Glucogen-like peptide—Amylin
- Glucocerebrosidase—Genzyme
- glutamate decarboxylase—Genzyme Transgenics
- Glycoprotein S3—Kureha
- GM-CSF—Immunex
- GM-CSF tumour vaccine—PowderJect
- GnRH immunotherapeutic—Protherics
- Goserelin (LhRH antagonist)—AstraZeneca
- gp75 antigen—ImClone
- gp96—Antigenics
- GPI 0100—Galenica
- GR 4991W93—GlaxoSmithKline
- Granulocyte colony-stimulating factor—Dong-A
- Granulocyte colony-stimulating factor conjugate
- grass allergy therapy—Dynavax
- GRF1-44 ICN
- Growth Factor—Chiron, Atrigel, Atrix, Innogenetics, ZymoGenetics, Novo
- growth factor peptides—Biotherapeutics
- growth hormone—LG Chem
- growth hormone, Recombinant human—Serono
- GT 4086—Gliatech
- GW 353430—GlaxoSmithKline
- GW-278884—GlaxoSmithKline
- H 11—Viventia Biotech
- H5N1 influenza A virus vaccine—Protein Sciences
- haemoglobin—Biopure
- haemoglobin 3011, Recombinant—Baxter Healthcare
- haemoglobin crosfumaril—Baxter Intl.
- haemoglobin stabilized—Ajinomoto
- haemoglobin, recombinant—Apex
- HAF—Immune Response
- Hantavirus vaccine
- HB 19
- HBNF—Regeneron
- HCC-1—Pharis
- hCG—Milkhaus
- hCG vaccine—Zonagen
- HE-317—Hollis-Eden Pharmaceuticals
- Heat shock protein cancer and influenza vaccines—StressGen
- Helicobacter pylori vaccine—Acambis, AstraZeneca/CSL, Chiron, Provalis
- Helistat-G—GalaGen
- Hemolink—Hemosol
- hepapoietin—Snow Brand
- heparanase—InSight
- heparinase I—Ibex
- heparinase III—Ibex
- Hepatitis A vaccine—American Biogenetic Sciences
- Hepatitis A vaccine inactivated
- Hepatitis A vaccine Nothav—Chiron
- Hepatitis A-hepatitis B vaccine—GlaxoSmithKline
- hepatitis B therapy—Tripep
- Hepatitis. B vaccine—Amgen, Chiron SpA, Meiji Milk, NIS, Prodeva, PowderJect, Rhein Biotech
- Hepatitis B vaccine recombinant—Evans Vaccines, Epitec Combiotech, Genentech, MedImmune, Merck Sharp & Dohme, Rhein Biotech, Shantha Biotechnics, Vector, Yeda
- Hepatitis B vaccine recombinant TGP 943—Takeda
- Hepatitis C vaccine—Bavarian Nordic, Chiron, Innogenetics Acambis
- Hepatitis D vaccine—Chiron Vaccines
- Hepatitis E vaccine recombinant—Genelabs/GlaxoSmithKline, Novavax
- hepatocyte growth factor—Panorama, Sosei
- hepatocyte growth factor kringle fragments—EntreMed
- Her-2/Neu peptides—Corixa
- Herpes simplex glycoprotein DNA vaccine—Merck, Wyeth-Lederle Vaccines-Malvern, Genentech, GlaxoSmithKline, Chiron, Takeda
- Herpes simplex vaccine—Cantab Pharmaceuticals, CEL-SCI, Henderson Morley
- Herpes simplex vaccine live—ImClone Systems/Wyeth-Lederle, Aventis Pasteur
- HGF derivatives—Dompe
- hIAPP vaccine—Crucell
- Hib-hepatitis B vaccine—Aventis Pasteur
- HIC 1
- HIP—Altachem
- Hirudins—Biopharma, Cangene, Dongkook, Japan Energy Corporation, Pharmacia Corporation, SIR International, Sanofi-Synthelabo, Sotragene, Rhein Biotech
- HIV edible vaccine—ProdiGene
- HIV gp120 vaccine—Chiron, Ajiomoto, GlaxoSmithKline, ID Vaccine, Progenics, VaxGen
- HIV gp120 vaccine gene therapy
- HIV gp160 DNA vaccine—PowderJect, Aventis Pasteur, Oncogen, Hyland Immuno, Protein Sciences
- HIV gp41 vaccine—Panacos
- HIV HGP-30W vaccine—CEL-SCI
- HIV immune globulin—Abbott, Chiron
- HIV peptides—American Home Products
- HIV vaccine—Applied bioTech., Axis Genetics, Biogen, Bristol-Myers Squibb, Genentech, Korea Green Cross, NIS, Oncogen, Protein Sciences Corporation, Terumo, Tonen Corporation, Wyeth-Ayerst, Wyeth-Lederle Vaccines-Malvern, Advanced BioScience Laboratories, Bavarian Nordic, Bavarian Nordic/Statens Serum Institute, GeneCure, Immune Response, Progenics, Therion Biologics, United Biomedical, Chiron
- HIV vaccine vCP1433—Aventis Pasteur
- HIV vaccine vCP1452—Aventis Pasteur
- HIV vaccine vCP205—Aventis Pasteur
- HL-9—American BioScience
- HM-9239—Cytran
- HML-103—Hemosol
- HML-104—Hemosol
- HML-105—Hemosol
- HML-109—Hemosol
- HML-110—Hemosol
- HML-121—Hemosol
- hNLP—Pharis
- Hookworm vaccine
- host-vector vaccines—Henogen
- HPM 1—Chugai
- HPV vaccine—MediGene
- HSA—Meristem
- HSF—StressGen
- HSP carriers—Weizmann, Yeda, Peptor
- HSPPC-70—Antigenics
- HSPPC-96, pathogen-derived—Antigenics
- HSV 863—Novartis
- HTLV-I DNA vaccine
- HTLV-I vaccine
- HTLV-II vaccine—Access
- HU 901—Tanox
- Hu23F2G—ICOS
- HuHMFG1
- HumaLYM—Intracell
- Human krebs statika—Yamanouchi
- human monoclonal antibodies—Abgenix/Biogen, Abgenix/Corixa, Abgenix/Immunex, Abgenix/Lexicon, Abgenix/Pfizer, Athersys/Medarex, Biogen/MorphoSys, CAT/Searle, Centocor/Medarex, Corixa/Kirin Brewery, Corixa/Medarex, Eos BioTech./Medarex, Eos/Xenerex, Exelixis/Protein Design Labs, ImmunoGen/Raven, Medarex/B.Twelve, MorphoSys/ImmunoGen, XTL Biopharmaceuticals/Dyax
- Human monoclonal antibodies—Medarex/Northwest Biotherapeutics, Medarex/Seattle Genetics
- human netrin-1—Exelixis
- human papillomavirus antibodies—Epicyte
- Human papillomavirus vaccine—Biotech Australia, IDEC, StressGen
- Human papillomavirus vaccine MEDI 501—MedImmune/GlaxoSmithKline
- Human papillomavirus vaccine MEDI 503/MEDI 504—MedImmune/GlaxoSmithKline
- Human papillomavirus vaccine TA-CIN—Cantab Pharmaceuticals
- Human papillomavirus vaccine TA-HPV—Cantab Pharmaceuticals
- Human papillomavirus vaccine TH-GW—Cantab/GlaxoSmithKline
- human polyclonal antibodies—Biosite/Eos BioTech./Medarex
- human type II anti factor VIII monoclonal antibodies—ThromboGenics
- humanised anti glycoprotein Ib murine monoclonal antibodies—ThromboGenics
- HumaRAD—Intracell
- HuMax EGFR—Genmab
- HuMax-CD4—Medarex
- HUMax-IL15—Genmab
- HYB 190—Hybridon
- HYB 676—Hybridon
- I-125 MAb A33—Celltech
- Ibritumomab tiuxetan—IDEC
- IBT-9401—Ibex
- IBT-9402—Ibex
- IC 14-ICOS
- Idarubicin anti-Ly-2.1
- IDEC 114—IDEC
- IDEC 131—IDEC
- IDEC 152—IDEC
- IDM 1—IDM
- IDPS—Hollis-Eden Pharmaceuticals
- iduronate-2-sulfatase—Transkaryotic Therapies
- IGF/IBP-2-13—Pharis
- IGN-101—Igeneon
- IK HIR02—Iketon
- IL-11—Genetics Institute/AHP
- IL-13-PE38—NeoPharm
- IL-17 receptor—Immunex
- IL-18BP—Yeda
- IL-1Hy1—Hyseq
- IL-1β—Celltech
- IL-1β adjuvant—Celltech
- IL-2—Chiron
- IL-2+IL-12—Hoffman LaRoche
- IL-6/sIL-6R fusion—Hadasit
- IL-6R derivative—Tosoh
- IL-7-Dap 389 fusion toxin—Ligand
- IM-862—Cytran
- IMC-1C11—ImClone
- imiglucerase—Genzyme
- Immune globulin intravenous (human)—Hoffman LaRoche
- immune privilege factor—Proneuron
- Immunocal—Immunotec
- Immunogene therapy—Briana Bio-Tech
- Immunoliposomal 5-fluorodeoxyuridine-dipalmitate
- immunosuppressant vaccine—Aixlie
- immunotoxin—Antisoma, NIH
- ImmuRAIT-Re-188—Immunomedics
- imreg-1—Imreg
- infertility—Johnson & Johnson, E-TRANS
- Infliximab—Centocor
- Influenza virus vaccine—Aventis Pasteur, Protein Sciences
- inhibin—Biotech Australia, Human Therapeutics
- Inhibitory G protein gene therapy
- INKP-2001—InKine
- Inolimomab—Diaclone
- insulin—Autoimmune, Altea, Biobras, BioSante, Bio-Tech. General, Chong Kun Dang, Emisphere, Flamel, Provalis, Rhein Biotech, TranXenoGen
- insulin (bovine)—Novartis
- insulin analogue—Eli Lilly
- Insulin Aspart—Novo Nordisk
- insulin detemir—Novo Nordisk
- insulin glargine—Aventis
- insulin inhaled—Inhale Therapeutics Systems, Alkermes
- insulin oral—Inovax
- insulin, AeroDose—AeroGen
- insulin, AERx—Aradigm
- insulin, BEODAS—Elan
- insulin, Biphasix—Helix
- insulin, buccal—Generex
- insulin, I2R—Flemington
- insulin, intranasal—Bentley
- insulin, oral—Nobex, Unigene
- insulin, Orasome—Endorex
- insulin, ProMaxx—Epic
- insulin, Quadrant—Elan
- insulin, recombinant—Aventis
- insulin, Spiros—Elan
- insulin, Transfersome—IDEA
- insulin, Zymo, recombinant—Novo Nordisk
- insulinotropin—Scios
- Insulysin gene therapy
- integrin antagonists—Merck
- interferon (Alpha2)—SRC VB VECTOR, Viragen, Dong-A, Hoffman La-Roche, Genentech
- interferon—BioMedicines, Human Genome Sciences
- interferon (Alfa-n3)—Interferon Sciences Intl.
- interferon (Alpha), Biphasix—Helix
- interferon (Alpha)—Amgen, BioNative, Novartis, Genzyme Transgenics, Hayashibara, Inhale Therapeutics Systems, Medusa, Flamel, Dong-A, GeneTrol, Nastech, Shantha, Wassermann, LG Chem, Sumitomo, Aventis, Behring EGIS, Pepgen, Servier, Rhein Biotech
- interferon (Alpha2A)
- interferon (Alpha2B)—Enzon, Schering-Plough, Biogen, IDEA
- interferon (Alpha-N1)—GlaxoSmithKline
- interferon (beta)—Rentschler, GeneTrol, Meristem, Rhein Biotech, Toray, Yeda, Daiichi, Mochida
- interferon (Beta1A)—Serono, Biogen
- interferon (beta1A), inhale—Biogen
- interferon (β1b)—Chiron
- interferon (tau)—Pepgen
- Interferon alfacon-1—Amgen
- Interferon alpha-2a vaccine
- Interferon Beta 1b—Schering/Chiron, InterMune
- Interferon Gamma—Boehringer Ingelheim, Sheffield, Rentschler, Hayashibara
- interferon receptor, Type I—Serono
- interferon(Gamma1B)—Genentech
- Interferon-alpha-2b+ribavirin—Biogen, ICN
- Interferon-alpha-2b gene therapy—Schering-Plough
- Interferon-con1 gene therapy
- interleukin-1 antagonists—Dompe
- Interleukin-1 receptor antagonist—Abbott Bioresearch, Pharmacia
- Interleukin-1 receptor type I—Immunex
- interleukin-1 receptor Type II—Immunex
- Interleukin-1 trap—Regeneron
- Interleukin-1-alpha—Immunex/Roche
- interleukin-2—SRC VB VECTOR, Ajinomoto, Biomira, Chiron IL-2/diphtheria toxin—Ligand
- Interleukin-3—Cangene
- Interleukin-4—Immunology Ventures, Sanofi Winthrop, Schering-Plough, Immunex/Sanofi Winthrop, Bayer, Ono
- interleukin-4+TNF-Alpha—NIH
- interleukin-4 agonist—Bayer
- interleukin-4 fusion toxin—Ligand
- Interleukin-4 receptor—Immunex, Immun
- Interleukin-6—Ajinomoto, Cangene, Yeda, Genetics Institute, Novartis
- interleukin-6 fusion protein
- interleukin-6 fusion toxin—Ligand, Serono
- interleukin-7—IC Innovations
- interleukin-7 receptor—Immunex
- interleukin-8 antagonists—Kyowa Hakko/Millennium/Pfizer
- interleukin-9 antagonists—Genaera
- Interleukin-10—DNAX, Schering-Plough
- Interleukin-10 gene therapy
- interleukin-12—Genetics Institute, Hoffman La-Roche
- interleukin-13—Sanofi
- interleukin-13 antagonists—AMRAD
- Interleukin-13-PE38QQR
- interleukin-15—Immunex
- interleukin-16—Research Corp
- interleukin-18—GlaxoSmithKline
- Interleukin-18 binding protein—Serono
- Ior-P3—Center of Molecular Immunology
- IP-10—NIH
- IPF—Metabolex
- IR-501—Immune Response
- ISIS 9125—Isis Pharmaceuticals
- ISURF No. 1554—Millennium
- ISURF No. 1866—Iowa State Univer.
- ITF-1697 Italfarmaco
- IxC 162—Ixion
- J 695—Cambridge Antibody Tech., Genetics Inst., Knoll
- Jagged+FGF—Repair
- JKC-362—Phoenix Pharmaceuticals
- JTP-2942—Japan Tobacce
- Juman monoclonal antibodies—Medarex/Raven
- K02—Axys Pharmaceuticals
- Keliximab—IDEC
- Keyhole limpet haemocyanin
- KGF—Amgen
- KM 871—Kyowa
- KPI 135—Scios
- KPI-022—Scios
- Kringle 5
- KSB 304
- KSB-201—KS Biomedix
- L 696418—Merck
- L 703801—Merck
- L1—Acorda
- L-761191—Merck
- lactoferrin—Meristem, Pharming, Agennix
- lactoferrin cardio—Pharming
- LAG-3—Serono
- LAIT—GEMMA
- LAK cell cytotoxin—Arizona
- lamellarins—PharmaMar/University of Malaga
- laminin A peptides—NIH
- lanoteplase—Genetics Institute
- laronidase—BioMarin
- Lassa fever vaccine
- LCAT—NIH
- LDP 01—Millennium
- LDP 02—Millennium
- Lecithinized superoxide dismutase—Seikagaku
- LeIF adjuvant—Corixa
- leishmaniasis vaccine—Corixa
- lenercept—Hoffman La-Roche
- Lenograstim—Aventis, Chugai
- lepirudin—Aventis
- leptin—Amgen, IC Innovations
- Leptin gene therapy—Chiron Corporation
- leptin, 2nd-generation—Amgen
- leridistim—Pharmacia
- leuprolide, ProMaxx—Epic
- leuprorelin, oral—Unigene
- LeuTech—Papatin
- LEX 032—SuperGen
- LiDEPT—Novartis
- Lintuzumab (anti-CD33 MAb)—Protein Design Labs
- lipase—Altus Biologics
- lipid A vaccine—EntreMed
- lipid-linked anchor Tech.—ICRT, ID Biomedical
- liposome-CD4 Tech.—Sheffield
- Listeria monocytogenes vaccine
- LMB 1
- LMB 7
- LMB 9—Battelle Memorial Institute, NIH
- LM-CD45 Cantab Pharmaceuticals
- lovastatin—Merck
- LSA-3
- LT-β receptor—Biogen
- lung cancer vaccine—Corixa
- lusupultide—Scios
- L-Vax—AVAX
- LY 355455—Eli Lilly
- LY 366405—Eli Lilly
- LY-355101—Eli Lilly
- Lyme disease DNA vaccine—Vical/Aventis Pasteur
- Lyme disease vaccine—Aquila Biopharmaceuticals, Aventis, Pasteur, Symbicom, GlaxoSmithKline, Hyland Immuno, MedImmune
- Lymphocytic choriomeningitis virus vaccine
- lymphoma vaccine—Biomira, Genitope
- LYP18
- lys plasminogen, recombinant
- Lysosomal storage disease gene therapy—Avigen
- lysostaphin—Nutrition 21
- M 23—Gruenenthal
- M1 monoclonal antibodies—Acorda Therapeutics
- MA 16N7C2—Corvas Intl.
- malaria vaccine—GlaxoSmithKline, AdProTech, Antigenics, Apovia, Aventis Pasteur, Axis Genetics, Behringwerke, CDCP, Chiron Vaccines, Genzyme Transgenics, Hawaii, MedImmune, NIH, NYU, Oxxon, Roche/Saramane, Biotech Australia, Rx Tech
- Malaria vaccine CDC/NIIMALVAC-1
- malaria vaccine, multicomponent
- mammaglobin—Corixa
- mammastatin—Biotherapeutics
- mannan-binding lectin—Natimmu
- mannan-MUC1—Psiron
- MAP 30
- Marinovir—Phytera
- MARstem—Maret
- MB-015—Mochida
- MBP—ImmuLogic
- MCI-028—Mitsubishi-Tokyo
- MCIF—Human Genome Sciences
- MDC—Advanced BioScience—Akzo Nobel, ICOS
- MDX 11—Medarex
- MDX 210—Medarex
- MDX 22—Medarex
- MDX 22
- MDX 240—Medarex
- MDX 33
- MDX 44—Medarex
- MDX 447—Medarex
- MDX H210—Medarex
- MDX RA—Houston BioTech., Medarex
- ME-104—Pharmexa
- Measles vaccine
- Mecasermin—Cephalon/Chiron, Chiron
- MEDI 488—MedImmune
- MEDI 500
- MEDI 507—BioTransplant
- melanin concentrating hormone—Neurocrine Biosciences
- melanocortins—OMRF
- Melanoma monoclonal antibodies—Viragen
- melanoma vaccine—GlaxoSmithKline, Akzo Nobel, Avant, Aventis Pasteur, Bavarian Nordic, Biovector, CancerVax, Genzyme Molecular Oncology, Humbolt, ImClone Systems, Memorial, NYU, Oxxon
- Melanoma vaccine Magevac—Therion
- memory enhancers—Scios
- meningococcal B vaccine—Chiron
- meningococcal vaccine—CAMR
- Meningococcal vaccine group B conjugate—North American Vaccine
- Meningococcal vaccine group B recombinant—BioChem Vaccines, Microscience
- Meningococcal vaccine group Y conjugate—North American Vaccine
- Meningococcal vaccine groups A B and C conjugate—North American Vaccine
- Mepolizumab—GlaxoSmithKline
- Metastatin—EntreMed, Takeda
- Met-CkB7—Human Genome Sciences
- met-enkephalin—TNI
- METH-1—Human Genome Sciences
- methioninase—AntiCancer
- Methionine lyase gene therapy—AntiCancer
- Met-RANTES—Genexa Biomedical, Serono
- Metreleptin
- Microtubule inhibitor MAb Immunogen/Abgenix
- MGDF—Kirin
- MGV—Progenics
- micrin—Endocrine
- microplasmin—ThromboGenics
- MIF—Genetics Institute
- migration inhibitory factor—NIH
- Mim CD4.1—Xycte Therapies
- mirostipen—Human Genome Sciences
- Mitumomab (BEC-2)—ImClone Systems, Merck KGaA
- MK 852—Merck
- MLN 1202 (Anti-CCR2 monoclonal antibody)—Millenium Pharmaceuticals
- Mobenakin—NIS
- molgramostim—Genetics Institute, Novartis
- monoclonal antibodies—Abgenix/Celltech, lmmusol/Medarex, Viragen/Roslin Institute, Cambridge Antibody Tech./Elan
- MAb 108
- MAb 10D5-εMAb 14.18-interleukin-2 immunocytokine—Lexigen
- MAb 14G2a
- MAb 15A10□MAb 170—Biomira
- MAb 177Lu CC49□MAb 17F9
- MAb 1D7
- MAb 1F7—Immune Network
- MAb 1H10-doxorubicin conjugate
- MAb 26-2F
- MAb 2A11
- MAb 2E1—RW Johnson
- MAb 2F5
- MAb 31.1—International Biolmmune Systems
- MAb 32—Cambridge Antibody Tech., Peptech
- MAb 323A3—Centocor
- MAb 3C5
- MAb 3F12
- MAb 3F8
- MAb 42/6
- MAb 425—Merck KGaA
- MAb 447-52D—Merck Sharp & Dohme
- MAb 45-2D9—haematoporphyrin conjugate
- MAb 4B4
- MAb 4E3-CPA conjugate—BCM Oncologia
- MAb 4E3-daunorubicin conjugate
- MAb 50-6
- MAb 50-61A—Institut Pasteur
- MAb 5A8—Biogen
- MAb 791T/36-methotrexate conjugate
- MAb 7c11.e8
- MAb 7E11 C5-selenocystamine conjugate
- MAb 93KA9—Novartis
- MAb A5B7-cisplatin conjugate—Biodynamics Research, Pharmacia
- MAb A5B7-I-131
- MAb A7
- MAb A717—Exocell
- MAb A7-zinostatin conjugate
- MAb ABX-RB2—Abgenix
- MAb ACA 11
- MAb AFP-I-131—Immunomedics
- MAb AP1
- MAb AZ1
- MAb B3-LysPE40 conjugate
- MAb B4—United Biomedical
- MAb B43 Genistein-conjugate
- MAb B43.13-Tc-99m Biomira
- MAb B43-PAP conjugate
- MAb B4G7-gelonin conjugate
- MAb BCM 43-daunorubicin conjugate—BCM Oncologia
- MAb BIS-1
- MAb BMS 181170—Bristol-Myers Squibb
- MAb BR55-2
- MAb BW494
- MAb C242-DM1 conjugate—ImmunoGen
- MAb C242-PE conjugate
- MAb c30-6
- MAb CA208-cytorhodin-S conjugate—Hoechst Japan
- MAb CC49—Enzon
- MAb ch14.1
- MAb CH14.18-GM-CSF fusion protein—Lexigen
- MAb chCE7
- MAb CI-137—AMRAD
- MAb cisplatin conjugate
- MAb CLB-CD19
- MAb CLB-CD19v
- MAb CLL-1—Peregrine
- MAb CLL-1-GM-CSF conjugate
- MAb CLL-1-IL-2 conjugate—Peregrine
- MAb CLN IgG—doxorubicin conjugates
- MAb conjugates—Tanox
- MAb D612
- MAb Dal B02
- MAb DC101—ImClone
- MAb EA 1
- MAb EC708—Biovation
- MAb EP-5C7—Protein Design Labs
- MAb ERIC-1—ICRT
- MAb F105 gene therapy
- MAb FC 2.15
- MAb G250—Centocor
- MAb GA6
- MAb GA733
- MAb Gliomab-H—Viventia Biotech
- MAb HB2-saporin conjugate
- MAb HD 37
- MAb HD37-ricin chain-A conjugate
- MAb HNK20—Acambis
- MAb huN901-DM1 conjugate—ImmunoGen
- MAb I-131 CC49—Corixa
- MAb ICO25
- MAb ICR12-CPG2 conjugate
- MAb ICR-62
- MAb IRac-ricin A conjugate
- MAb K1
- MAb KS1-4-methotrexate conjugate
- MAb L6—Bristol-Myers Squibb, Oncogen
- MAb LiCO 16-88
- MAb LL2-I-131—Immunomedics
- MAb LL2-Y-90
- MAb LS2D617—Hybritech
- MAb LYM-1-gelonin conjugate
- MAb LYM-1-I-131
- MAb LYM-1-Y-90
- MAb LYM-2—Peregrine
- MAb M195
- MAb M195-bismuth 213 conjugate—Protein Design Labs
- MAb M195-gelonin conjugate
- MAb M195-I-131
- MAb M195-Y-90
- MAb MA 33H1—Sanofi
- MAb MAD11
- MAb MGb2
- MAb MINT5
- MAb MK2-23
- MAb MOC31 ETA(252-613) conjugate
- MAb MOC-31-In-111
- MAb MOC-31-PE conjugate
- MAb MR6
- MAb MRK-16—Aventis Pasteur
- MAb MS11G6
- MAb MX-DTPA BrE-3
- MAb MY9
- MAb Nd2—Tosoh
- MAb NG-1—Hygeia
- MAb NM01—Nissin Food
- MAb OC 125
- MAb OC 125-CMA conjugate
- MAb OKI-1—Ortho-McNeil
- MAb OX52—Bioproducts for Science
- MAb PMA5
- MAb PR1
- MAb prost 30
- MAb R-24
- MAb R-24α Human GD3—Celltech
- MAb RFB4-ricin chain A conjugate
- MAb RFT5-ricin chain A conjugate
- MAb SC 1
- MAb SM-3 ICRT
- MAb SMART 1D10—Protein Design Labs
- MAb SMART ABL 364—Novartis
- MAb SN6f
- MAb SN6f-deglycosylated ricin A chain conjugate
- MAb SN6j
- MAb SN7-ricin chain A conjugate
- MAb T101-Y-90 conjugate—Hybritech
- MAb T-88—Chiron
- MAb TB94—Cancer ImmunoBiology
- MAb TEC 11
- MAb TES-23—Chugai
- MAb TM31—Avant
- MAb TNT-1—Cambridge Antibody Tech., Peregrine
- MAb TNT-3
- MAb TNT-3—IL2 fusion protein
- MAb TP3-At-211
- MAb TP3-PAP conjugate
- MAb UJ13A—ICRT
- MAb UN3
- MAb ZME-018-gelonin conjugate
- MAb-BC2—GlaxoSmithKline
- MAb-DM1 conjugate—ImmunoGen
- MAb-ricin-chain-A conjugate—XOMA
- MAb-temoporfin conjugates
- Monopharm C—Viventia Biotech
- monteplase—Eisai
- montirelin hydrate—Gruenenthal
- moroctocog alfa—Genetics Institute
- Moroctocog-alfa—Pharmacia
- MP 4
- MP-121—Biopharm
- MP-52—Biopharm
- MRA—Chugai
- MS 28168—Mitsui Chemicals, Nihon Schering
- MSH fusion toxin—Ligand
- MSI-99—Genaera
- MT 201—Micromet
- Muc-1 vaccine—Corixa
- Mucosal tolerance—Aberdeen
- mullerian inhibiting subst
- muplestim—Genetics Institute, Novartis, DSM Anti-Infectives
- murine MAb—KS Biomedix
- Mutant somatropin—JCR Pharmaceutical
- MV 833—Toagosei
- Mycoplasma pulmonis vaccine
- Mycoprex—XOMA
- myeloperoxidase—Henogen
- myostatin—Genetics Institute
- Nacolomab tafenatox—Pharmacia
- Nagrecor—Scios
- nagrestipen—British Biotech
- NAP-5—Corvas Intl.
- NAPc2—Corvas Intl.
- nartograstim—Kyowa
- Natalizumab—Protein Design Labs
- Nateplase—NIH, Nihon Schering
- nateplase—Schering AG
- NBI-3001—Neurocrine Biosci.
- NBI-5788—Neurocrine Biosci.
- NBI-6024—Neurocrine Biosci.
- Nef inhibitors—BRI
- Neisseria gonorrhoea vaccine—Antex Biologics
- Neomycin B-arginine conjugate
- Nerelimomab—Chiron
- Nerve growth factor—Amgen—Chiron, Genentech
- Nerve growth factor gene therapy
- nesiritide citrate—Scios
- neuregulin-2—CeNeS
- neurocan—NYU
- neuronal delivery system—CAMR
- Neurophil inhibitory Factor—Corvas
- Neuroprotective vaccine—University of Auckland
- neurotrophic chimaeras—Regeneron
- neurotrophic factor—NsGene, CereMedix
- NeuroVax—Immune Response
- neurturin—Genentech
- neutral endopeptidase—Genentech
- NGF enhancers—NeuroSearch
- NHL vaccine—Large Scale Biology
- NIP45—Boston Life Sciences
- NKI-B20
- NM 01—Nissin Food
- NMI-139—NitroMed
- NMMP—Genetics Institute
- NN-2211—Novo Nordisk
- Noggin—Regeneron
- Nonacog alfa
- Norelin—Biostar
- Norwalk virus vaccine
- NRLU 10—NeoRx
- NRLU 10 PE—NeoRx
- NT-3—Regeneron
- NT-4/5—Genentech
- NU 3056
- NU 3076
- NX 1838—Gilead Sciences
- NY ESO-1/CAG-3 antigen—NIH
- NYVAC-7—Aventis Pasteur
- NZ-1002—Novazyme
- obesity therapy—Nobex
- OC 10426—Ontogen
- OC 144093—Ontogen
- OCIF—Sankyo
- Oct-43—Otsuka
- Odulimomab—Immunotech
- OK PSA—liposomal
- OKT3-gamma-1-ala-ala
- OM991
- OM 992
- Omalizumab—Genentech
- oncoimmunin-L—NIH
- Oncolysin B—ImmunoGen
- Oncolysin CD6—ImmunoGen
- Oncolysin M—ImmunoGen
- Oncolysin S—ImmunoGen
- Oncophage—Antigenics
- Oncostatin M—Bristol-Myers Squibb
- Onco Vax-CL—Jenner Biotherapies
- Onco Vax-P—Jenner Biotherapies
- onercept—Yeda
- onychomycosis vaccine—Boehringer Ingelheim
- opebecan—XOMA
- opioids—Arizona
- Oprelvekin—Genetics Institute
- Oregovomab—AltaRex
- Org-33408 b—Akzo Nobel
- Orolip DP—EpiCept
- Oryzacystatin
- OSA peptides—GenSci Regeneration
- osteoblast-cadherin GF—Pharis
- Osteocalcin-thymidine kinase gene therapy
- osteogenic protein—Curis
- osteopontin—OraPharma
- osteoporosis peptides—Integra, Telios
- osteoprotegerin—Amgen, SnowBrand
- otitis media vaccines—Antex Biologics
- ovarian cancer—University of Alabama
- OX40-IgG fusion protein—Cantab, Xenova
- P 246—Diatide
- P 30—Alfacell
- p1025—Active Biotech
- P-113̂—Demegen
- P-16 peptide—Transition Therapeutics
- p43—Ramot
- P-50 peptide—Transition Therapeutics
- p53+RAS vaccine—NIH, NCI
- PACAP(1-27) analogue
- paediatric vaccines—Chiron
- Pafase—ICOS
- PAGE-4 plasmid DNA—IDEC
- PAI-2—Biotech Australia, Human Therapeutics
- Palifermin (keratinocyte growth factor)—Amgen
- Palivizumab—MedImmune
- PAM 4—Merck
- pamiteplase—Yamanouchi
- pancreatin, Minitabs—Eurand
- Pangen—Fournier
- Pantarin—Selective Genetics
- Parainfluenza virus vaccine—Pharmacia, Pierre Fabre
- paraoxanase—Esperion
- parathyroid hormone—Abiogen, Korea Green Cross
- Parathyroid hormone (1-34)—Chugai/Suntory
- Parkinson's disease gene therapy—Cell Genesys/Ceregene
- Parvovirus vaccine—MedImmune
- PCP-Scan—Immunomedics
- PDGF—Chiron
- PDGF cocktail—Theratechnologies
- peanut allergy therapy—Dynavax
- PEG anti-ICAM MAb—Boehringer Ingelheim
- PEG asparaginase—Enzon
- PEG glucocerebrosidase
- PEG hirudin—Knoll
- PEG interferon-alpha-2a—Roche
- PEG interferon-alpha-2b+ribavirin—Biogen, Enzon, ICN Pharmaceuticals, Schering-Plough
- PEG MAb A5B7
- Pegacaristim—Amgen—Kirin Brewery—ZymoGenetics
- Pegaldesleukin—Research Corp
- pegaspargase—Enzon
- pegfilgrastim—Amgen
- PEG-interferon Alpha—Viragen
- PEG-interferon Alpha 2A—Hoffman LaRoche
- PEG-interferon Alpha 2B—Schering-Plough
- PEG-r-hirudin—Abbott
- PEG-rHuMGDF—Amgen
- PEG-uricase—Mountain View
- Pegvisomant—Genentech
- PEGylated proteins, PoIyMASC—Valentis
- PEGylated recombinant native human leptin—Roche
- Pemtumomab
- Penetratin—Cyclacel
- Pepscan—Antisoma
- peptide G—Peptech, ICRT
- peptide vaccine—NIH, NCI
- Pexelizumab
- pexiganan acetate—Genaera
- Pharmaprojects No. 3179—NYU
- Pharmaprojects No. 3390—Ernest Orlando
- Pharmaprojects No. 3417—Sumitomo
- Pharmaprojects No. 3777—Acambis
- Pharmaprojects No. 4209—XOMA
- Pharmaprojects No. 4349—Baxter Intl.
- Pharmaprojects No. 4651
- Pharmaprojects No. 4915—Avanir
- Pharmaprojects No. 5156—Rhizogenics
- Pharmaprojects No. 5200—Pfizer
- Pharmaprojects No. 5215—Origene
- Pharmaprojects No. 5216—Origene
- Pharmaprojects No. 5218—Origene
- Pharmaprojects No. 5267—ML Laboratories
- Pharmaprojects No. 5373—MorphoSys
- Pharmaprojects No. 5493—Metabolex
- Pharmaprojects No. 5707—Genentech
- Pharmaprojects No. 5728—Autogen
- Pharmaprojects No. 5733—BioMarin
- Pharmaprojects No. 5757—NIH
- Pharmaprojects No. 5765—Gryphon
- Pharmaprojects No. 5830—AntiCancer
- Pharmaprojects No. 5839—Dyax
- Pharmaprojects No. 5849—Johnson & Johnson
- Pharmaprojects No. 5860—Mitsubishi-Tokyo
- Pharmaprojects No. 5869—Oxford GlycoSciences
- Pharmaprojects No. 5883—Asahi Brewery
- Pharmaprojects No. 5947—StressGen
- Pharmaprojects No. 5961—Theratechnologies
- Pharmaprojects No. 5962—NIH
- Pharmaprojects No. 5966—NIH
- Pharmaprojects No. 5994—Pharming
- Pharmaprojects No. 5995—Pharming
- Pharmaprojects No. 6023—IMMUCON
- Pharmaprojects No. 6063—Cytoclonal
- Pharmaprojects No. 6073—SIDDCO
- Pharmaprojects No. 6115—Genzyme
- Pharmaprojects No. 6227—NIH
- Pharmaprojects No. 6230—NIH
- Pharmaprojects No. 6236—NIH
- Pharmaprojects No. 6243—NIH
- Pharmaprojects No. 6244—NIH
- Pharmaprojects No. 6281—Senetek
- Pharmaprojects No. 6365—NIH
- Pharmaprojects No. 6368—NIH
- Pharmaprojects No. 6373—NIH
- Pharmaprojects No. 6408—Pan Pacific
- Pharmaprojects No. 6410—Athersys
- Pharmaprojects No. 6421—Oxford GlycoSciences
- Pharmaprojects No. 6522—Maxygen
- Pharmaprojects No. 6523—Pharis
- Pharmaprojects No. 6538—Maxygen
- Pharmaprojects No. 6554—APALEXO
- Pharmaprojects No. 6560—Ardana
- Pharmaprojects No. 6562—Bayer
- Pharmaprojects No. 6569—Eos
- Phenoxazine
- Phenylase—Ibex
- Pigment epithelium derived factor
- plasminogen activator inhibitor-1, recombinant—DuPont Pharmaceuticals
- Plasminogen activators—Abbott Laboratories, American Home Products, Boehringer Mannheim, Chiron Corporation, DuPont Pharmaceuticals, Eli Lilly, Shionogi, Genentech, Genetics Institute, GlaxoSmithKline, Hemispherx Biopharma, Merck & Co, Novartis, Pharmacia Corporation, Wakamoto, Yeda
- plasminogen-related peptides—Bio-Tech. General/MGH
- platelet factor 4—RepliGen
- Platelet-derived growth factor—Amgen—ZymoGenetics
- Plusonermin—Hayashibara
- PMD-2850—Protherics
- Pneumococcal vaccine—Antex Biologics, Aventis Pasteur
- Pneumococcal vaccine intranasal—BioChem Vaccines/Biovector
- PR1A3
- PR-39
- pralmorelin—Kaken
- Pretarget-Lymphoma—NeoRx
- Priliximab—Centocor
- PRO 140—Progenics
- PRO 2000—Procept
- PRO 367—Progenics
- PRO 542—Progenics
- pro-Apo A-I—Esperion
- prolactin—Genzyme
- Prosaptide TX14(A)—Bio-Tech. General
- prostate cancer antbodies—Immunex, UroCor
- prostate cancer antibody therapy—Genentech/UroGenesys, Genotherapeutics
- prostate cancer immunotherapeutics—The PSMA Development Company
- prostate cancer vaccine—Aventis Pasteur, Zonagen, Corixa, Dendreon, Jenner Biotherapies, Therion Biologics
- prostate-specific antigen—EntreMed
- protein A—RepliGen
- protein adhesives—Enzon
- protein C—Baxter Intl., PPL Therapeutics, ZymoGenetics
- protein C activator—Gilead Sciences
- protein kinase R antags—NIH
- protirelin—Takeda
- protocadherin 2—Caprion
- Pro-urokinase—Abbott, Bristol-Myers Squibb, Dainippon, Tosoh—Welfide
- P-selectin glycoprotein ligand-1—Genetics Institute
- pseudomonal infections—InterMune
- Pseudomonas vaccine—Cytovax
- PSGL-Ig—American Home Products
- PSP-94—Procyon
- PTH 1-34—Nobex
- Quilimmune-M—Antigenics
- R 744—Roche
- R 101933
- R 125224—Sankyo
- RA therapy—Cardion
- Rabies vaccine recombinant—Aventis Pasteur, BioChem Vaccines, Kaketsuken Pharmaceuticals
- RadíoTheraCIM—YM BioSciences
- Ramot project No. 1315—Ramot
- Ramot project No. K-734A—Ramot
- Ramot project No. K-734B—Ramot
- Ranibizumab (Anti-VEGF fragment)—Genentech
- RANK—Immunex
- ranpirnase—Alfacell
- ranpirnase-anti-CD22 MAb—Alfacell
- RANTES inhibitor—Milan
- RAPID drug delivery systems—ARIAD
- rasburicase—Sanofi
- rBPI-21, topical—XOMA
- RC 529—Corixa
- rCFTR—Genzyme Transgenics
- RD 62198
- rDnase—Genentech
- RDP-58—SangStat
- RecepTox-Fce—Keryx
- RecepTox-GnRH—Keryx, MTR Technologies
- RecepTox-MBP—Keryx, MTR Technologies
- recFSH—Akzo Nobel, Organon
- REGA 3G12
- Regavirumab—Teijin
- relaxin—Connetics Corp
- Renal cancer vaccine—Macropharm
- repifermin—Human Genome Sciences
- Respiratory syncytial virus PFP-2 vaccine—Wyeth-Lederle
- Respiratory syncytial virus vaccine—GlaxoSmithKline, Pharmacia, Pierre Fabre
- Respiratory syncytial virus vaccine inactivated
- Respiratory syncytial virus-parainfluenza virus vaccine—Aventis Pasteur, Pharmacia
- Reteplase—Boehringer Mannheim, Hoffman LaRoche
- Retropep—Retroscreen,
- RFB4 (dsFv) PE38
- RFI 641—American Home Products
- RFTS—UAB Research Foundation
- RG 12986—Aventis Pasteur
- RG 83852—Aventis Pasteur
- RG-1059—RepliGen
- rGCR—NIH
- rGLP-1—Restoragen
- rGRF—Restoragen
- rh Insulin—Eli Lilly
- RHAMM targeting peptides—Cangene
- rHb1.1—Baxter Intl.
- rhCC10—Claragen
- rhCG—Serono
- Rheumatoid arthritis gene therapy
- Rheumatoid arthritis vaccine—Veterans Affairs Medical Center
- rhLH—Serono
- Ribozyme gene therapy—Genset
- Rickettsial vaccine recombinant
- RIGScan CR—Neoprobe
- RIP-3—Rigel
- Rituximab—Genentech
- RK-0202—RxKinetix
- RLT peptide—Esperion
- rM/NEI—IVAX
- rmCRP—Immtech
- RN-1001—Renovo
- RN-3—Renovo
- RNAse conjugate—Immunomedics
- RO 631908—Roche
- Rotavirus vaccine—Merck
- RP 431—DuPont Pharmaceuticals
- RP-128—Resolution
- RPE65 gene therap
- RPR 110173—Aventis Pasteur
- RPR 115135—Aventis Pasteur
- RPR 116258A—Aventis Pasteur
- rPSGL-Ig—American Home Products
- r-SPC surfactant—Byk Gulden
- RSV antibody—Medimmune
- Ruplizumab—Biogen
- rV-HER-2/neu—Therion Biologics
- SA 1042—Sankyo
- sacrosidase—Orphan Medical
- Sant 7
- Sargramostim—Immunex
- saruplase—Gruenenthal
- Satumomab—Cytogen
- SB 1—COR Therapeutics
- SB 207448—GlaxoSmithKline
- SB 208651—GlaxoSmithKline
- SB 240683—GlaxoSmithKline
- SB 249415—GlaxoSmithKline
- SB 249417—GlaxoSmithKline
- SB 6—COR Therapeutics
- SB RA 31012
- SC 56929—Pharmacia
- SCA binding proteins—Curis, Enzon
- scFv(14E1)-ETA Berlex Laboratories, Schering AG,
- ScFv(FRP5)-ETA
- ScFv6C6-PE40
- SCH 55700—Celltech
- Schistosomiasis vaccine—Glaxo Wellcome/Medeva, Brazil
- SCPF—Advanced Tissue Sciences
- scuPA-suPAR complex—Hadasit
- SD-9427—Pharmacia
- SDF-1—Ono
- SDZ 215918—Novartis
- SDZ 280125—Novartis
- SDZ 89104—Novartis
- SDZ ABL 364—Novartis
- SDZ MMA 383—Novartis
- Secretin—Ferring, Repligen
- serine protease inhibs—Pharis
- sermorelin acetate—Serono
- SERP-1—Viron
- sertenef—Dainippon
- serum albumin, Recombinant human—Aventis Behring
- serum-derived factor—Hadasit
- Sevirumab—Novartis
- SGN 14—Seatle Genetics
- SGN 15—Seatle Genetics
- SGN 17/19—Seatle Genetics
- SGN 30—Seatle Genetics
- SGN-10—Seatle Genetics
- SGN-11—Seatle Genetics
- SH 306—DuPont Pharmaceuticals
- Shanvac-B—Shantha
- Shigella flexneri vaccine—Avant, Acambis, Novavax
- Shigella sonnei vaccine
- sICAM-1—Boehringer Ingelheim
- Silteplase—Genzyme
- SIV vaccine—Endocon, Institut Pasteur
- SK 896—Sanwa Kagaku Kenkyusho
- SK-827—Sanwa Kagaku Kenkyusho
- Skeletex—CellFactors
- SKF 106160—GlaxoSmithKline
- S-nitroso-AR545C
- SNTP—Active Biotech
- somatomedin-1 GroPep, Mitsubishi-Tokyo, NIH
- somatomedin-1 carrier protein—Insmed
- somatostatin—Ferring
- Somatotropin/Human Growth Hormone—Bio-Tech. General, Eli Lilly
- somatropin—Bio-Tech. General, Alkermes, ProLease, Aventis Behring, Biovector, Cangene, Dong-A, Eli Lilly, Emisphere, Enact, Genentech, Genzyme Transgenics, Grandis/InfiMed, CSL, InfiMed, MacroMed, Novartis, Novo Nordisk, Pharmacia Serono, TranXenoGen
- somatropin derivative—Schering AG
- somatropin, AIR—Eli Lilly
- Somatropin, inhaled—Eli Lilly/Alkermes
- somatropin, Kabi—Pharmacia
- somatropin, Orasome—Novo Nordisk
- Sonermin—Dainippon Pharmaceutical
- SP(V5.2)C—Supertek
- SPf66
- sphingomyelinase—Genzyme
- SR 29001—Sanofi
- SR 41476—Sanofi
- SR-29001—Sanofi
- SS1(dsFV)-PE38—NeoPharm
- β2 microglobulin—Avidex
- β2-microglobulin fusion proteins—NIH
- β-amyloid peptides—CeNeS
- β-defensin—Pharis
- Staphylococcus aureus infections—Inhibitex/ZLB
- Staphylococcus aureus vaccine conjugate—Nabi
- Staphylococcus therapy—Tripep
- Staphylokinase—Biovation, Prothera, Thrombogenetics
- Streptococcal A vaccine—M6 Pharmaceuticals, North American Vaccine
- Streptococcal B vaccine—Microscience
- Streptococcal B vaccine recombinant—Biochem Vaccines
- Streptococcus pyogenes vaccine
- STRL-33—NIH
- Subalin—SRC VB VECTOR
- SUIS—United Biomedical
- SUIS-LHRH—United Biomedical
- SUN-E3001—Suntory
- super high affinity monoclonal antibodies—YM BioSciences
- Superoxide dismutase—Chiron, Enzon, Ube Industries, Bio-Tech, Yeda
- superoxide dismutase-2—OXIS
- suppressin—UAB Research Foundation
- SY-161-P5—ThromboGenics
- SY-162—ThromboGenics
- Systemic lupus erythematosus vaccine—MedClone/VivoRx
- T cell receptor peptides—Xoma
- T cell receptor peptide vaccine
- T4N5 liposomes—AGI Dermatics
- TACI, soluble—ZymoGenetics
- targeted apoptosis—Antisoma
- tasonermin—Boehringer Ingelheim
- TASP
- TASP-V
- Tat peptide analogues—NIH
- TBP I—Yeda
- TBP II
- TBV25H—NIH
- Tc 99m ior cea1—Center of Molecular Immunology
- Tc 99m P 748—Diatide
- Tc 99m votumumab—Intracell
- Tc-99m rh-Annexin V—Theseus Imaging
- teceleukin—Biogen
- tenecteplase—Genentech
- Teriparatide—Armour Pharmaceuticals, Asahi Kasei, Eli Lilly
- terlipressin—Ferring
- testisin—AMRAD
- Tetrafibricin—Roche
- TFPI—EntreMed
- tgD-IL-2—Takeda
- TGF-Alpha—ZymoGenetics
- TGF-β—Kolon
- TGF-β2—Insmed
- TGF-β3—OSI
- Thalassaemia gene therapy—Crucell
- TheraCIM-h-R3—Center of Molecular Immunology, YM BioSciences
- Theradigm-HBV—Epimmune
- Theradigm-HPV—Epimmune
- Theradigm-malaria—Epimmune
- Theradigm-melanoma—Epimmune
- TheraFab—Antisoma
- ThGRF 1-29—Theratechnologies
- ThGRF 1-44—Theratechnologies
- Thrombin receptor activating peptide—Abbott
- thrombomodulin—Iowa, Novocastra
- Thrombopoietin—Dragon Pharmaceuticals, Genentech
- thrombopoietin, Pliva—Receptron
- Thrombospondin
- thrombostatin—Thromgen
- thymalfasin—SciClone
- thymocartin—Gedeon Richter
- thymosin Alpha1—NIH
- thyroid stimulating hormone—Genzyme
- tICAM-1—Bayer
- Tick anticoagulant peptide—Merck
- TIF—Xoma
- Tifacogin—Chiron, NIS, Pharmacia
- Tissue factor—Genentech
- Tissue factor pathway inhibitor
- TJN-135—Tsumura
- TM 27—Avant
- TM 29—Avant
- TMC-151—Tanabe Seiyaku
- TNF tumour necrosis factor—Asahi Kasei
- TNF Alpha—CytImmune
- TNF antibody—Johnson & Johnson
- TNF binding protein—Amgen
- TNF degradation product—Oncotech
- TNF receptor—Immunex
- TNF receptor 1, soluble—Amgen
- TNF Tumour necrosis factor-alpha—Asahi Kasei, Genetech, Mochida
- TNF-Alpha inhibitor—Tripep
- TNFR:Fc gene therapy—Targeted Genetics
- TNF-SAM2
- ToleriMab—Innogenetics
- Toxoplasma gondii vaccine—GlaxoSmithKline
- TP 9201—Telios
- TP10—Avant
- TP20—Avant
- tPA—Centocor
- trafermin—Scios
- TRAIL/Apo2L—Immunex
- TRAIL-R1 MAb—Cambridge Antibody Technologies
- transferrin-binding proteins—CAMR
- Transforming growth factor-beta-1—Genentech
- transport protein—Genesis
- Trastuzumab—Genetech
- TRH—Ferring
- Triabin—Schering AG
- Triconal
- Triflavin
- troponin I—Boston Life Sciences
- TRP-2̂—NIH
- trypsin inhibitor—Mochida
- TSP-1 gene therapy
- TT-232
- TTS-CD2—Active Biotech
- Tuberculosis vaccine—Aventis Pasteur, Genesis
- Tumor Targeted Superantigens—Active Biotech—Pharmacia
- tumour vaccines—PhotoCure
- tumour-activated prodrug antibody conjugates—Millennium/ImmunoGen
- tumstatin—ILEX
- Tuvirumab—Novartis
- TV-4710—Teva
- TWEAK receptor—Immunex
- TXU-PAP
- TY-10721—TOA Eiyo
- Type I diabetes vaccine—Research Corp
- Typhoid vaccine CVD 908
- U 143677—Pharmacia
- U 81749—Pharmacia
- UA 1248—Arizona
- UGIF—Sheffield
- UIC 2
- UK 101
- UK-279276—Corvas Intl
- urodilatin—Pharis
- urofollitrophin—Serono
- Urokinase—Abbott
- uteroferrin—Pepgen
- V 20—GLYCODesign
- V2 vasopressin receptor gene therapy
- vaccines—Active Biotech
- Varicella zoster glycoprotein vaccine—Research Corporation Technologies
- Varicella zoster virus vaccine live—Cantab Pharmaceuticals
- Vascular endothelial growth factor—Genentech, University of California
- Vascular endothelial growth factors—R&D Systems
- vascular targeting agents—Peregrine
- vasopermeation enhancement agents—Peregrine
- vasostatin—NIH
- VCL—Bio-Tech. General
- VEGF—Genentech, Scios
- VEGF inhibitor—Chugai
- VEGF-2—Human Genome Sciences
- VEGF-Trap—Regeneron
- viscumin, recombinant—Madaus
- Vitaxin
- Vitrase—ISTA Pharmaceuticals
- West Nile virus vaccine—Bavarian Nordic
- WP 652
- WT1 vaccine—Corixa
- WX-293—Wilex BioTech.
- WX-360—Wilex BioTech.
- WX-UK1—Wilex BioTech.
- XMP-500—XOMA
- XomaZyme-791—XOMA
- XTL 001—XTL Biopharmaceuticals
- XTL 002—XTL Biopharmaceuticals
- yeast delivery system—GlobeImmune
- Yersinia pestis vaccine
- YIGSR-Stealth—Johnson & Johnson
- Yissum Project No. D-0460—Yissum
- YM 207—Yamanouchi
- YM 337—Protein Design Labs
- Yttrium-90 labelled biotin
- Yttrium-90-labeled anti-CEA MAb T84.66
- ZD 0490—AstraZeneca
- ziconotide—Elan
- ZK 157138—Berlex Laboratories
- Zolimomab aritox
- Zorcell—Immune Response
- ZRXL peptides—Novartis

In certain embodiments, a therapeutic agent such as insulin is associated with a composition of the invention. Association of insulin with the lipid-based constituents comprising a composition of the invention is achieved via combination of a low molarity solution of insulin with an aqueous suspension of the lipid-based constituents. In this embodiment, the number of lipid molecules involved in the assembly of the lipid-based constituents comprising the composition far surpasses the number of molecules of insulin. This high lipid to insulin ratio minimizes the molecular interactions between insulin and the lipids, insuring that the self-assembly and self-organization process of the lipid-based constituents are not disrupted. This high ratio also facilitates the formation of a stable insulin/composition construct.

Without wishing to be bound by a particular theory, it is believed that the quantity of therapeutic agent(s) associated with the composition of the present invention appears to be a function of loading time, lipid concentration, and buffer molarity. As the lipid concentration in aqueous media is increased, additional therapeutic agents associate with a composition of the present invention. The time required for loading the therapeutic agent may be anywhere from several hours to about one week.

The low concentration of therapeutic agent relative to the concentration of the composition is unique among lipid particle delivery systems. Typically, liposome or liposome-like delivery systems have employed a much larger quantity of therapeutic agent. The efficacy of this embodiment shows that it is possible to utilize less therapeutic agent while still obtaining a pharmacologically desirable result in the patient. This embodiment of the invention therefore provides an advantageous therapeutic option.

In other embodiments the addition of a higher concentration of therapeutic agent may be both desirable and advantageous. The composition of the present invention is capable of associating with, and tolerating, higher molarity solutions of any given therapeutic agent.

A diagrammatic example of insulin associated with a composition of the invention is depicted in FIG. 1.

Serotonin, like insulin, may also be delivered to the liver utilizing a composition including an HTM. Serotonin acts jointly with insulin at the level of the liver to activate hepatic glucose storage during a portal (oral) glucose load. In order to achieve the desired effect, serotonin must be delivered to the liver. Non-targeted serotonin, introduced via injection or oral delivery in pharmacologically acceptable doses cannot effectively induce the desired activity. Therefore, an embodiment of the invention includes a composition comprising an HTM with associated serotonin. This embodiment provides a highly desirable delivery mechanism for this important gluco-regulatory hormone. In an embodiment of the invention designed for the delivery of serotonin, the lipids comprising the composition are approximately 61 mole percent, 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol and about 1 mole percent of a targeting agent.

Calcitonin is a hormone that regulates bone metabolism. Due to the high prevalence of diseases such as osteoporosis, an oral formulation of this hormone is highly desirable. Presently calcitonin is only deliverable via injection. In an embodiment of the invention designed for the delivery of calcitonin, the lipids selected to form the composition include approximately 62 mole percent, 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, and approximately 16 mole percent cholesterol.

GLP-1 is a peptide that acts at both the liver and pancreas. In the liver, GLP-1 acts to stimulate glycogen accumulation during a meal. However, prior art administration methods where GLP-1 is administered orally evidence poor bioavailability and reduced efficacy upon oral dosing. In an embodiment of the present invention, GLP-1 associates with a constituent of a composition of the invention form a constitutent/GLP-1 construct. The constituent/GLP-1 construct may further include a targeting agent. Preferably, the lipid components selected to form the constituents of the composition including GLP-1 include approximately 62 mole percent 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, and approximately 16 mole percent cholesterol.

Thyroxine, although orally bioaviable, is not selective when taken orally. In an embodiment of the invention, though, thyroxine may associate with the composition of the invention giving a constituent/thyroxine construct that may be specifically targeted to the liver, restricting thyroxine's action to that of lowering blood lipids and cholesterol. Preferably, the lipids selected to form the composition for associating thyroxine include approximately 62 mole percent, 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and approximately 1 mole percent Biotin DHPE.

Blood clotting Factors VII, VIII, IX, and X act in either the contact activation (intrinsic), tissue factor (extrinsic), or common pathways for blood clotting. These proteins are not presently orally bioavailable for treatment of diseases such as hemophilia. In an embodiment of the present invention, blood clotting factors VII, VIII, IX, and X may associate with a composition of the invention. Preferably the lipids selected to form the composition for associating one of factors VII, VIII, IX, or X include approximately 62 mole percent, 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and approximately 1 mole percent Biotin DHPE.

Although the invention has been described in terms of specific therapeutic agents and lipids noted above, any of the therapeutic agents described herein may associate with a composition of the invention, comprising any of the combination of lipids disclosed herein.

Covalent Association of Therapeutic and Diagnostic Agents

In embodiments of the invention, a therapeutic or diagnostic agent is covalently attached to a lipid. Examples of lipids to which the therapeutic agents may be attached include, for example, cholesterol, thiocholesterol, MPB-PE, MCC-PE, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol. Examples of therapeutic agents that may be covalently bound to a lipid include, but are not limited to, poly-peptides and/or proteins, such as, but not limited to, GLP-1, insulin, calcitonin, interferon, uricase, tissue plasminogen activator, thymoglobin, various vaccines, heparin, heparin analogs, antithrombin III, filgrastin, pramilitide acetate, exenatide, epifibatide, and antivenins, blood clotting factors including, but not limited to, Factors VII, VIII, IX, Kallikrein, Kininogen, Hageman Factor (XII), plasma thromboplastin antecedent Factor (XI), tissue factor, Stuart Factor (X), accelerin (V), prothrombin (II), and fibrin stabilizing Factor (XIII); various small molecules, such as, for example, D or L thyroxine or serotonin, nucleic acids, DNA or RNA sequences, immunoglobulins, such as, but not limited to, IgG and IgM, and a variety of monoclonal antibodies, such as but not limited to, rituximab, trastuzumab, and glycolipids that act as therapeutic agents, and in addition, other larger proteins, such as, for example, human growth hormone (“HGH”), erythropoietin, and parathyroid hormone. Various other therapeutic agents have been described elsewhere herein. Each of these therapeutic agents may likewise covalently associate with a composition of the invention.

Examples of diagnostic agents that may be covalently bound to a lipid include diagnostic contrast agents such as, but not limited to, gold, TEMPO (2-diacyl-sn-glycerol-3-phospho-TEMPO-choline), Fe⁺²oxide, Fe⁺³oxide, and gadolinium. Other diagnostic agents include radioactive materials such as radioactive isotopes of common atoms including, but not limited to, ¹³C, ⁶⁸Ge, ¹⁸F, and ¹²⁵I. These contrast and radioactive agents may be covalently attached to a lipid or to the optionally present targeting agent. Alternatively, and where chemically appropriate, the diagnostic agent may be bound to a ligand such as DADO (2′-deoxyadenosine), which is itself covalently attached to a lipid or the optional targeting agent. Alternatively, diagnostic agents, such as those described above, may be covalently linked to an antibody or small molecule. These antibodies or small molecules may then associate with a composition of the invention for subsequent oral delivery.

In one embodiment, a therapeutic or diagnostic agent may be directly attached to a lipid. In this embodiment, a free carboxylate or aldehyde on a therapeutic agent is condensed with a lipid bearing an amine using known procedures. Alternatively, the carboxylate may form an ester with a lipid bearing a free alcohol using known esterification procedures. In an alternative embodiment, a free thiol on a therapeutic agent may form a disulfide linkage with a lipid also presenting a free thiol.

More typically, however, a therapeutic agent is attached to a given lipid via a linker. As an example, a therapeutic agent may be attached to a lipid as follows: (therapeutic agent)-N—C(O)(CH₂)_nS-lipid. In this embodiment, the linker is —C(O)(CH₂)_nS—. This linker is derived from reaction of a succinimidyl based linker precursor, succinimidyl-O—C(O)(CH₂)_nSR. Preferably, n is an integer between 1 and 10. Even more preferably, n is 1, 2, or 3. R is typically a protecting group such as —C(O)CH₃. Other appropriate thiol protecting groups may be found in Green's Protective Groups in Organic Synthesis, Wuts, et al, 4^thedition, 2007.

Generally speaking, the linker precursor reacts with a nucleophilic amine, alcohol, or thiol present on the therapeutic agent, displacing N-hydroxysuccinimide, to form an amide, ester, or thioester. Preferably, the nucleophile is a primary amine. After the linker is bound to the therapeutic agent, the protecting group, R, is removed from the linker to reveal a thiol. Preferably, the protecting group is removed under conditions that do not perturb the now attached therapeutic agent. This thiol may then undergo a Michael reaction with a lipid such as MPB-PE or MCC-PE. Preferably, lipids MPB-PE and/or MCC-PE are already incorporated into a composition of the invention, however, the Michael reaction may take place pior to incorporating these lipids into a composition of the invention. The order of reactions will depend upon the therapeutic agent's ability to tolerate microfluidization, aqueous environments, and elevated temperatures. In the case of complex proteins which may denature at high temperatures, it is preferable to perform the Michael reaction after MPB-PE and/or MCC-PE have been incorporated into a composition of the invention.

Additional linker precursors that may be used include compounds according to formula I:

wherein “A” corresponds to

or NH₂NH—; “J” corresponds to (CH₂)_aor

and G¹is either H or SO₃Na. Subscript “a” is independently, at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8. Common examples of linker precurors according to formula I include, but are not limited to, N-succinimidyl-3-(2-pyridyldithio)proprionate (“SPDP”), Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (“LC-SPDP”), Sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate (“Sulfo-LC-SPDP”), 4-Succinimidyloxycarbonyl-methyl-a-[2-pyridyldithio]toluene (“SMPT”), 4-Sulfosuccinimidyl-6-methyl-a-(2-pyridyldithio)toluamido]hexanoate) (“Sulfo-LC-SMPT”), and 3-(2-pyridyldithio)propionyl hydrazide (“PDPH”), each of which are known and described in the literature.

When a compound of formula I is used (and “A” is not NH₂NH) a free nitrogen on a therapeutic agent reacts with the compound of formula I to form an amide bond by displacing N-hydroxysuccinimide or a related derivative. Subsequently, the disulfide bridge present in the linker precursor is reduced under mild conditions using tris(2-carboxyethyl)phosphine (TCEP) or other known reducing agents. The resulting free thiol can then react with a lipid such as MPB-PE or MCC-PE, either before or after the lipid is incorporated into a composition of the invention. Preferably, the resulting free thiol is reacted with the lipid after the lipid has been incorporated into a composition of the invention.

Alternatively, a compound of formula I may react with a nucleophile such as 1,2-distearoyl-sn-glycero-3-phosphethanolamine, or related derivative, to displace succinimide. The disulfide in the resulting product may then be reduced using TCEP or other mild reductant to provide a free thiol. The resulting thiol compound may then be oxidatively coupled to a free thiol in a therapeutic agent. Preferably, the resulting free thiol is reacted with the therapeutic agent after the lipid has been incorporated into a composition of the invention, however it need not be, depending upon the stability of the therapeutic agent.

When A is NH₂NH—, the nucleophilic nitrogen of the hydrazide reacts with a ketone, aldehyde, activated ester, a carboxylic acid, or leaving group on a therapeutic agent to form a therapeutic agent/linker conjugate. When reacting with an aldehyde or ketone, the reaction is typically a reductive amination, but may be a simple condensation without concomitant reduction, resulting in the formation of an enamine. When the hydrazide reacts with a carboxylic acid to form a hydrazone, the reaction is mediated by a crosslinking reagent, such as EDC, EDCI, or other crosslinking reagent now known or hereafter developed.

As above, the disulfide bridge is then reduced under mild conditions. The resulting free thiol can then react with a lipid such as MPB-PE or MCC-PE, either before or after the lipid is incorporated into a composition of the invention. Preferably, the resulting free thiol is reacted with the lipid after the lipid has been incorporated into the composition.

In another embodiment, the linker precursor may be a compound according to formula II

wherein G¹is either H or SO₃Na; G²is maleimidyl,

—HNC(O)CH₂I, —CH₂NHC(O)(CH₂)_aNHC(O)CH₂I, —CH₂HNC(O)CH₂I; “Q” is optional and, when present, is —C(O)(CH₂)_aNH—; “K” is optional, and when present, is —(CH₂)_a—; and “a,” as used in formula II, “Q”, or “K” is independently, at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8. When “A” is not present, the oxygen of the N-hydroxysuccinimidyl group is bound directly to the carbon of the carbonyl adjacent to “A”.

In formula II, the bond notation indicates that the bond may be a single or a double bond. Preferably, when one bond according to the above described notation represents a double bond, all bonds according to that notation represent double bonds. Similarly, if any bond according to the above described notation represents a single bond, it is preferred that all bonds according to that notation represent a single bond.

Common examples of linker precursors according to formula II include, but are not limited to, Succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (“SMCC”), Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (“Sulfo-SMCC”), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (“MBS”), m-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester (“Sulfo-MBS”), N-Succinimidyl[4-iodoacetyl]aminobenzoate (“SIAB”), N-Sulfosuccinimidyl[4-iodoacetyl]aminobenzoate (“Sulfo-SIAB”), succinimidyl-4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate (“SIAC”), succinimidyl 4-[p-maleimidophenyl]butyrate (“SMPB”), sulfosuccinimidyl 4-[p-maleimidophenyl]butyrate (“Sulfo-SMPB”), and succinimidyl-6-((((4-(iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate (“SIACX”), each of which are known and described in the literature.

When a compound of formula II is used, a free nitrogen on a therapeutic agent reacts with the compound of formula II to form an amide bond by displacing N-hydroxysuccinimide or sulfo-N-hydroxysuccinimide. The resulting therapeutic agent/linker conjugate is then preferably reacted with a composition of the invention containing a lipid bearing a free thiol (such as, for example, thiocholesterol or 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol). The free thiol undergoes a Michael reaction into the double bond of a maleimide group, or displaces I⁻ in a displacement reaction. Although it is preferred that the therapeutic agent/linker conjugate is reacted with a lipid presenting a free thiol that has already been incorporated into a composition of the invention, the therapeutic agent/linker conjugate may be reacted with a lipid presenting a free thiol prior to the lipid being incorporated into a composition of the invention.

In another embodiment, the linker precursor may be a compound according to formula III

wherein G¹is either H or SO₃Na, G⁴is maleimidyl, —HNC(O)CH₂I, or NHC(O)(CH₂)_aNHC(O)CH₂I and “a” is, independently at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8. A double dashed bond connected to an oxygen indicates that a given carbon is optionally a carbonyl. Thus, in formula III, the double dashed bond connected to the noted carbon indicates that the bond connectivity at that carbon is —C(O)— or —CH₂—. Common examples of linker precursors according to formula III include, but are not limited to, N-[g-maleimidobutyryloxy]succinimide ester (“GMBS”), N-[g-maleimidobutyryloxy]sulfosuccinimide ester (“Sulfo-GMBS”), succinimidyl-6-((iodoacetyl)amino)hexanoate (“SIAX”), and succinimidyl-6-(6-(((iodoacetyl)amino)hexanoyl)amino)hexanoate (“SIAXX”), each of which are known and described in the literature.

When a compound of formula III is used, a free nitrogen on a therapeutic agent reacts with the compound of formula III to form an amide bond by displacing N-hydroxysuccinimide or sulfo-N-hydroxysuccinimide. The resulting therapeutic agent/linker conjugate is then preferably reacted with a composition of the invention containing a lipid bearing a free thiol (such as, for example, thiocholesterol or 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol). The free thiol undergoes a Michael reaction into the double bond of a maleimide group, or displaces I⁻ in a displacement reaction. Although it is preferred that the therapeutic agent/linker conjugate is reacted with a lipid presenting a free thiol that has already been incorporated into a composition of the invention, the therapeutic agent/linker conjugate may be reacted with a lipid presenting a free thiol prior to the lipid being incorporation into a composition of the invention.

In another embodiment, the linker precursor may be compounds according to formula IV

When a compound of formula IV is used, a free nitrogen on a therapeutic agent reacts with the compound of formula IV to form an amide bond by displacing the p-nitrophenyl group. The resulting therapeutic agent/linker conjugate is then preferably reacted with a composition of the invention containing a lipid bearing a free thiol (such as, for example, thiocholesterol or 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol). The free thiol displaces I⁻ in a displacement reaction. Although it is preferred that the therapeutic agent/linker conjugate is reacted with a lipid presenting a free thiol that has already been incorporated into a composition of the invention, the therapeutic agent/linker conjugate may be reacted with a lipid presenting a free thiol prior to the lipid being incorporated into a composition of the invention.

In a further embodiment, the linker precursor is a compound of formula V.

In formula V, “Z” is independently optional at each occurrence, and when present is (CH₂)_a. Subscript “a” is independently, at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8. Although structure V is shown as the salt, compounds of formula V may be either a salt or a free base. Examples of linker precursors according to formula V include, but are not limited to, 4-(4-N-Maleimidophenyl)butyric acid hydrazide hydrochloride (“MBPH”) and 4-(N-maleimidophenyl)cyclohexane-1-carbonyl-hydrazide hydrochloride (“M₂C₂H”). In formula V, the bond notationindicates that the bond may be a single or a double bond. Preferably, when one bond according to the above described notation represents a double bond, all bonds according to that notation represent double bonds. Similarly, if any bond according to the above described notation represents a single bond, it is preferred that all bonds according to that notation represent a single bond.

When a compound of formula V is used, the nucleophilic nitrogen of the hydrazide reacts with a ketone, aldehyde, activated ester, a carboxylic acid, or leaving group on a therapeutic agent to form a therapeutic agent/linker conjugate. When reacting with an aldehyde or ketone, the reaction is typically a reductive amination. The reaction may, however, be a simple condensation without concomitant reduction, resulting in the formation of an enamine. When the hydrazide is reacted with a carboxylic acid, the reaction is mediated by a crosslinking reagent, such as EDC (1-ethyl-3,3-dimethylaminopropylcarbodiimide), EDCI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), or other crosslinking reagent now known or hereafter developed.

The resulting therapeutic agent/linker conjugate is then preferably reacted with a composition of the invention containing a lipid bearing a free thiol (such as, for example, thiocholesterol or 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol). The free thiol undergoes a Michael reaction into the double bond of the maleimide portion of the conjugate. Although it is preferred that the therapeutic agent/linker conjugate is reacted with a lipid presenting a free thiol that has already been incorporated into a composition of the invention, the therapeutic agent/linker conjugate may be reacted with a lipid presenting a free thiol prior to the lipid being incorporated into a composition of the invention.

In a further embodiment, the linker precursor may be a compound according to formula VI:

wherein G⁵is selected from the group consisting of —C(O)G⁷, —C(O)NHNH₂, —C(O)C(O)H, —C(O)NH(CH₂)_aNH₂, —C(O)NH(CH₂)_aNHC(O)CH₂I, —C(O)NH(CH₂)_aC(O)G⁷, —NO₂, —(CH₂)_aNHC(O)G⁷, —NH(CH₂)_aC(O)G⁷, —(CH₂)_aSSC(O)G⁷, —C(O)NH(CH₂)_aSS(CH₂)_aC(O)G⁷, —(CH₂)_aC(O)G⁷, and —C(O)NH(CH₂)_aNHC(O)(CH₂)_aG⁹; “a” is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8; and G⁶is selected from the group consisting —OH, —NO₂, —H, and —C(O)G⁷. G⁷is

wherein G¹is either H or —SO₃Na; provided that G⁶is —C(O)G⁷only when G⁵is —NO₂and that G⁵is —NO₂only when G⁶is —C(O)G⁷. G⁹is

Examples of linkers according formula VI include, but are not limited to, N-Hydroxysuccinimidyl-4-azidosalicylic acid (“NHS-ASA”), N-hydroxysulfosuccinimidyl-4-azidosalicylic acid (“Sulfo-NHS-ASA”), sulfosuccinimidyl[4-azidosalicylamido]-hexanoate (“Sulfo-NHS-LC-ASA”), N-hydroxysuccinimidyl-4-azidobenzoate (“HSAB”), N-hydroxysulfosuccinimidyl-4-azidobenzoate (“Sulfo-HSAB”), N-5-azido-2-nitrobenzoyloxysuccinimide (“ANB-NOS”), N-succinimidyl-6-(4′-azido-2′-nitrophenylamino)hexanoate (“SANPAH”), N-sulfosuccinimidyl-6-(4′-azido-2′-nitrophenylamino)hexanoate (“Sulfo-SANPAH”), N-succinimidyl(4-azidophenyl)-1,3′-dithioproprionate (“SADP”), N-Sulfosuccinimidyl(4-azidophenyl)-1,3′-dithioproprionate (“Sulfo-SADP”), sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl-1,3′-dithiopropionate (“SASD”), 1-(p-azidosalicylamido)-4-(iodoacetamido)butane (“ASIB”), N-[4-(p-azidosalicylamido)butyl]-3′-(2′-pyridyldithio)propionamide (“APDP”), p-azidobenzoyl hydrazide (“ABH”), 4-[p-azidosalicylamido]butylamine (“ASBA”), p-azidophenyl glyoxal (“APG”), and sulfosuccinimidyl-4-(p-azidophenyl)butyrate (“Sulfo-SAPB”), each of which are known and described in the literature.

Linker precursors according to formula VI may be used in various ways. In an example of a first method of attachment wherein G⁵or G⁶is a group containing G⁷, a free nitrogen on an therapeutic agent reacts with the linker precursor giving a therapeutic agent/linker conjugate by displacing N-hydroxysuccinimide or sulfo-N-hydroxysuccinimide. The resulting conjugate is then irradiated with UV light in the presence of a substantial excess of a lipid. The UV light induces nitrene formation. This nitrene subsequently reacts with the lipid in a non-selective manner to form a therapeutic agent/linker/lipid conjugate. This conjugate can then be incorporated into a composition of the invention.

In an alternative process, a therapeutic agent/linker conjugate may be irradiated with UV light in the presence of a composition of the invention. The UV light induces nitrene formation. This nitrene can then react with any lipid present in the composition.

In another embodiment, the linker precursor according to formula VI may be irradiated in the presence of a lipid or a composition of the invention prior to reaction with a therapeutic agent. This process results in the formation of a lipid/linker conjugate or a composition/linker conjugate. The lipid/linker conjugate is subsequently incorporated into a composition of the invention according to the procedures set forth elsewhere herein. The composition/linker conjugate may then be reacted with a therapeutic agent presenting a nucleophilic nitrogen according to the displacement chemistry described previously herein.

When G⁵in formula VI is a group containing a nucleophilic nitrogen, this nucleophilic nitrogen may react with a ketone, aldehyde, activated ester, a carboxylic acid, or leaving group on a therapeutic agent to form a therapeutic agent/linker conjugate. When reacting with an aldehyde or ketone, the reaction is typically a reductive amination. The reaction may, however, be a simple condensation without concomitant reduction, resulting in the formation of an enamine. When the nucleophilic nitrogen reacts with a carboxylic acid, the reaction is mediated by a crosslinking reagent, such as EDC, EDCI, or other crosslinking reagent now known or hereafter developed.

The resulting therapeutic agent/linker conjugate is then preferably irradiated with UV light in the presence of a substantial excess of a lipid, as described above, to form a therapeutic agent/linker/lipid conjugate. This conjugate can then be incorporated into a composition. In an alternative procedure, the therapeutic agent/linker conjugate may be irradiated in the presence of composition of the invention.

In yet another embodiment, the linker precursor of formula VI may be irradiated in the presence of a lipid or a composition of the invention prior to reaction with a therapeutic agent. This process results in the formation of a lipid/linker conjugate or a composition/linker conjugate. The lipid/linker conjugate is subsequently incorporated into a composition of the invention according to the procedures set forth elsewhere herein. The composition/linker conjugate may then be reacted with a therapeutic agent with a nucleophilic nitrogen according to the displacement chemistry described previously.

In an alternative embodiment, a linker precursor according to formula VI may be irradiated and reacted with a therapeutic agent to form a therapeutic agent/linker conjugate. When the conjugate contains a group according to G⁷, the conjugate may then be reacted with a compound such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, wherein the free nitrogen of the ethanolamine reacts with the activated hydroxy succinimidyl ester of G⁷. If the conjugate contains a “CH₂I” functionality, the conjugate may be reacted with a lipid such as thiocholesterol. If the conjugate contains a disulfide, this disulfide may be selectively reduced, whereupon the resulting free thiol bound to the conjugate may react with a compound such as MPB-PE or MCC-PE. Preferably, the lipids used to bind the therapeutic agent/linker conjugate have already been incorporated into a composition of the invention.

In any of the above described procedures, the order of reactions and the choice of coupling partner will be determined by the stability of the therapeutic agent under a particular set of reaction conditions. It is within the skill of the ordinarily skilled artisan to determine the appropriate order of reactions to arrive at the desired bond connectivity.

In a further embodiment, the linker precursor may be a compound according to formula VII or VIII:

wherein G¹is either H or SO₃Na and G⁸is selected from the group consisting of 2-nitrophenyl-5-azido and

Subscript “a” is independently, at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8. Examples of compounds according to formula VII and VIII include, but are not limited to, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3′-proprionate (“SAND”), sulfosuccinimidyl 2-[7-amino-4-methylcoumarin-3-acetamido]ethyl-1,3′dithiopropionate (“SAED”), and sulfo-succinimidyl 7-azido-4-methylcoumarin-3-acetate (“Sulfo-SAMCA”). Linker precursors according to formula VII and VIII may be utilized in substantially the same ways as described with respect to linker precursors of formula VI.

In a further embodiment, the linker precursor may be a compound according to formula IX:

wherein G¹⁰is selected from the group consisting of maleimidyl and NC(O)CH₂I. Examples of linker precursors according to formula IX include, but are not limited to, benzophenone-4-iodoacetamide and benzophenone-4-maleimide. When using a linker precursor of formula IX, the free thiol of thiocholesterol displaces I⁻ in a displacement reaction to form a linker/lipid conjugate. Subsequently, the linker/lipid conjugate is irradiated with UV light in the presence of a therapeutic agent to form a therapeutic agent/linker/lipid conjugate. This compound may then be incorporated into a composition of the invention.

In a further embodiment, the linker precursor may be a compound according to formula X:

wherein G¹¹is selected from the group consisting of C(O)C(N₂)H and C(N₂)CF₃. When a linker precursor according to formula X is used, the linker precursor is first reacted with a therapeutic agent containing a free primary amine in order displace p-nitrophenol. This results in a therapeutic agent/linker conjugate. Subsequently, the conjugate is irridated to form a carbene. When G¹¹is C(O)C(N₂)H, the conjugate is irradiated in the presence of a compound containing a nucleophilic amine, such as, for example, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine. When G¹¹is C(N₂)CF₃, the conjugate is irradiated in the presence of lipid or a composition of the invention.

Alternatively, the compound according to Formula X may first be reacted with a lipid such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine to displace p-nitrophenol and then irridated to form a carbene. When G¹¹is C(O)C(N₂)H, the conjugate is irradiated in the presence of a therapeutic agent containing a nucleophilic amine. When G¹¹is C(N₂)CF₃, the conjugate is irradiated in the presence of a therapeutic agent.

As with other reactions described herein, the order of reactions and the choice of coupling partner will be determined by the stability of the therapeutic agent under a particular set of reaction conditions. It is within the skill of the ordinarily skilled artisan to determine the appropriate order of reactions to arrive at the desired bond connectivity.

RES Masking and Avoidance

In addition to an optional targeting molecule, the composition of the invention may further include a reticuloendothelial sytem (RES) avoidance molecule. The RES avoidance molecule gives the composition a longer half life in the systemic circulation by shielding the composition from macrophage detection.

RES avoidance molecules may be incorporated into a composition of the invention by binding to a lipid comprising the composition of the invention. For example, U.S. Pat. No. 6,177,099 describes a process wherein B-methoxy neuraminic acid was modified to contain a free thiol that was subsequently reacted with MPB-PE via a Michael reaction, as shown in Scheme 1.

Along with the incorporation of neuraminic acid as described above, the present invention further contemplates the incorporation of other novel neuraminic acid derivatives. These novel derivatives include, but are not limited to the following N-acyl neuraminic acid derivatives:

Although not shown, further examples of neuraminic acid derivatives include those in which the nitrogen is not acylated.

The above described neuraminic acid derivatives may be linked to a lipid of the invention via various methodologies. In one embodiment, an N-acyl neuraminic acid derivative containing a 1,2 diol functionality may be cleaved to an aldehyde using NaIO₄under known conditions. The resulting aldehyde may then undergo reductive amination with the primary amine of a lipid such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine according to known procedures. An example of this chemistry is shown in Scheme 2.

In an alternative embodiment, an N-acyl neuraminic acid derivative may be reacted with a phosgene equivalent such as N,N′-disuccinimidylcarbonate (DSC). In this embodiment, an alcohol on the neuraminic acid derivative reacts with DSC to produce an intermediate containing an activated carbonyl. This intermediate can then be reacted with a lipid presenting a free primary or secondary amine. A non-limiting example of an amine bearing lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine.

In a further embodiment, cholesterol may react with DSC to form intermediate that may be subsequently reacted with neuraminic acid derivative presenting a free amine.

In still another embodiment, a neuraminic acid derivative presenting a free amine may be condensed with formaldehyde to generate an iminium, which may be quenched by nucleophilic attack at the formaldehyde carbon with an appropriate nucleophile. Appropriate nucleophiles include primary and secondary amines, an example of which includes, but is not limited to, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine.

As discussed elsewhere herein, RES masking agents may also be associated with a composition of the invention via non-covalent interactions. In the non-covalent embodiment, up to about 10 mole percent of the composition may comprise one or more RES masking agents.

Stability

Although a composition of the invention is formulated in aqueous media, the composition does not exhibit long term stability in water. Specifically, water aids hydrolysis of any acyl chains present in any of the lipids present in the composition. The aqueous environment also allows for the ready oxidation of any unsaturated acyl chains present in any of these lipids. In a preferred embodiment of the present invention, the composition of the present invention may be protected for long term storage via interaction with a proteoglycan such as a modified collagen, known generically as dry granulated gelatin. Dry granulated gelatin, when contacted with an aqueous suspension of a composition of the invention, reacts with the water, and stabilizes the composition.

The reaction of dried granulated gelatin with an aqueous suspension of a composition of the present invention results in a semi-solid colloidal gel that shields the composition from direct interaction with water. Any water not associated with gelatin is slowly evaporated via refrigerated storage at about 2° to about 8° C. The water may, however, be removed via techniques including, but not limited to, freeze drying and spray drying.

This results in a pellet like “dry” composition/gelatin complex. In the complex, the composition of the invention is partially dehydrated in a reversible manner and sequestered by the proteinaceous lattice of dry gelatin. This sequestration is enabled by structured water, structured lipid and structured gelatin all interacting through hydrogen bonding, ionic bonding, van der Waal's interactions, and hydrophobic bonding between the lipids, water, and protein structures, such as, for example, insulin. This evidences that gelatin is not acting as an emulsifying or suspending agent. As a result, the “dry” pellet is stable for long term storage because the activity of water has been mitigated. These pellets can be further processed to a granulated or free-flowing powder for final capsule filling or tabletting, while maintaining their stability.

Upon oral administration to a patient, the “dry” pellet becomes hydrated and once again assumes a semi-solid colloidal gel state. Upon further exposure to the gastric environment, the gel becomes liquid as gelatin is solubilized. Once the gelatin is completely solubilized, the composition of the invention rehydrates, resulting in the formation of a new suspension within the gastric environment. The reconstituted composition may then be absorbed into the portal blood flow.

It is important to realize that the role of gelatin in this aspect of the invention is as an active stabilizer of the composition and not an inert filler as is commonly found in oral formulations of many other pharmaceutical compositions. That said, the additional use of gelatin as an inert filler in addition to the aforementioned use is also contemplated.

Although gelatin is used in a preferred embodiment of the invention, other gelatin like compounds may be used as well. Examples of agents that will act as active stabilizers include, but are not limited to, acacia (gum arabic), agar (agar-agar; vegetable gelatin; gelosa; Chinese or Japanese gelatin), alginic acid, sodium alginate (alginic acid; sodium salt; algin; Manucol; Norgine; Kelgin), carbomer (carboxypolymethylene), carrageenan, carboxymethylcellulose sodium (carbose D; carboxymethocel S; CMC; cellulose gum), powdered cellulose (Degussa), hydroxyethyl cellulose (cellulose; 2-hydroxyethyl ether; Cellosize; Natrosol), hydroxypropyl cellulose (cellulose; 2-hydroxypropyl ether; Klucel), hydroxypropyl methylcellulose (cellulose; 2-hydroxypropyl methyl ether), methycellulose (cellulose; methyl ether Methocel), povidone(2-pyrrolidinone; 1-ethenyl-; homopolymer; polyvinylpyrrolidone), tragacanth (gum tragacanth; Hog Gum; Goat's Thorn), and xanthan gum (Keltrol). Like gelatin, and where appropriate, these compounds may also be used as inert fillers.

Formulations

A formulation of a composition of the invention and therapeutic agent (with or without the targeting agent)—hereinafter “composition”—for oral administration may be prepared, packaged, or sold in the form of a discrete solid dose unit including, but not limited to, a tablet, a hard or soft capsule, a cachet, a troche, or a lozenge, each containing a predetermined amount of the active ingredient. Other formulations suitable for oral administration include, but are not limited to, a powdered or granular formulation, aqueous suspensions, or emulsions.

A tablet comprising the composition of the present invention, for example, be made by compressing or molding the composition optionally with one or more additional ingredients. Compressed tablets may be prepared by compressing, in a suitable device, the composition in a free-flowing form such as a powder or granular preparation, optionally mixed with one or more of a binder, a lubricant, an excipient, a surface active agent, and a dispersing agent. Molded tablets may be made by molding, in a suitable device, the composition, a pharmaceutically acceptable carrier, and at least sufficient liquid to moisten the mixture.

Pharmaceutically acceptable excipients used in the manufacture of tablets include, but are not limited to, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. Known dispersing agents include, but are not limited to, potato starch and sodium starch glycollate. Known surface active agents include, but are not limited to, sodium lauryl sulphate. Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate. Known granulating and disintegrating agents include, but are not limited to, corn starch and alginic acid. Known binding agents include, but are not limited to, gelatin, acacia, pre-gelatinized maize starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Known lubricating agents include, but are not limited to, magnesium stearate, stearic acid, silica, and talc.

Tablets may be non-coated or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the composition. By way of example, a material such as glyceryl monostearate or glyceryl distearate may be used to coat tablets. Further by way of example, tablets may be coated using methods described in U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotically-controlled release tablets. Tablets may further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some combination of these in order to provide pharmaceutically elegant and palatable preparation.

Hard capsules comprising the composition may be made using a physiologically degradable composition, such as gelatin. Such hard capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, kaolin or cellulose acetate hydrogen phthalate.

Soft gelatin capsules comprising the composition may be made using a physiologically degradable composition, such as gelatin.

Liquid formulations of the composition which are suitable for oral administration may be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or another suitable vehicle prior to use, subject to the stability limitations disclosed earlier.

Liquid suspensions may be prepared using conventional methods to achieve suspension of the constituents in an aqueous vehicle. Aqueous vehicles include, for example, water and isotonic saline. Oily vehicles may only be used to the extent that such solvents are not incompatible with the constituents of the composition of the present invention. To the extent that an oily suspension is not incompatible with the constituents of the composition of the present invention, an oily suspension may further comprise a thickening agent.

Liquid suspensions may further comprise one or more additional ingredients to the extent that said ingredients do not disrupt the structures of the constituents of the composition of the invention. Examples of additional ingredients include, but are not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents.

Known suspending agents include, but are not limited to, sorbitol syrup, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose.

Known emulsifying agents include, but are not limited to acacia. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl-para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin.

Powdered and granular formulations of a pharmaceutical preparation of the invention may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous suspension or solution by addition of an aqueous vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.

Methods of Treating Diseases

Diseases, such as diabetes, may be treated by orally administering a composition of the invention wherein insulin is the associated therapeutic agent. Similarly, diabetes may be treated by orally administering a compound of the invention wherein insulin is the associated therapeutic and wherein another form of insulin is co-administered. Routes of co-administration include, but are not limited to, oral administration, intramuscular injection, inhalation, intravenous injection, intra-arterial injection, as well as any other form of administration.

Although a physician will be able to select the appropriate dose for a given patient, the range of doses that may be delivered in a given formulation of a compound of the invention is from about 1 to about 40 units, but may be 5, 10, 15, 20, 25, 30, or 35 units. A given formulation may, however, contain any whole or partial integer therebetween and may exceed 40 units.

Of course, diseases other than diabetes may be treated by orally administering a composition of the invention with a different associated therapeutic agent. A person of ordinary skill in the art, armed with the disclosure herein, will be able to select a given therapeutic agent, associate that therapeutic agent with the composition of the invention, and treat a disease or condition susceptible to treatment with the therapeutic agent.

Kits

The invention also includes a kit comprising a composition of the invention and an instructional material which describes administering the composition to a mammal. As used herein, an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention in the kit for effecting alleviation of the various diseases or disorders recited herein.

Optionally, or alternatively, the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal. The instructional material of the kit may, for example, be affixed to a container which contains the invention or be shipped together with a container which contains the invention. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient.

EXPERIMENTAL EXAMPLES

The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Experiment 1—Administration of Compositions Not Containing a Targeting Agent

A composition prepared from a mixture of lipids including approximately 62 mole percent 1,2-distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and no targeting agent was prepared according to the microfluidization procedure generally described herein. A known portion of the lipid component comprised ¹⁴C labeled phospholipid. Following filtration through a 0.2 micron filter, the average constituent size was less than 100 nm as measured with a Coulter Sub-micron Particle Size Analyzer.

A 10 mg/kg body weight sample of the composition (containing 85,000 cpm of ¹⁴C radio-label) was then injected into the duodenum of an anesthetized 230 gram fasted, but otherwise normal, rat. Blood was taken from the portal and femoral veins at 15 and 30 minutes post-dosing for counting (FIG. 2). At 30 minutes post-dosing, the rat was sacrificed and representative samples of blood, liver, and spleen were removed for analysis (FIG. 3).

Labeled composition, as measured by ¹⁴C, was found in both portal and femoral blood of the rat. The portal blood levels of ¹⁴C labeled composition was higher than the femoral blood levels (FIG. 2). At 30 minutes post-dosing, approximately 15% of the composition that was injected into the gut was found in the blood. Approximately 4% of the counts were found in the liver and about 1% were found in the spleen. Considering the relative sizes of the liver and spleen, the splenic uptake was much higher than liver uptake on a weight basis.

Experiment 2—Hepatocyte Targeting

To demonstrate the absorption of the composition from the gut, a composition comprising insulin and approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and approximately 1 mole percent poly[Cr-bis(N-2,6-diisopropylphenylcarbamoylmethyl iminodiacetic acid)] (wherein a known portion of the phospholipid component comprised ¹⁴C labeled phospholipid) was prepared as recited in the general preparation disclosed herein. Prior to dosing the labeled composition to rats, the rats were fasted from food for 24 hours and from water for 4 hours. The fasted rats were then permitted to drink water from a graduated water bottle containing the composition. The drinking water bottle was removed from the cage after 15 minutes, the amount of water ingested from the drinking bottle was measured, and the amount of composition ingested was calculated. The rats' blood was sampled at 15, 30, and 45 minutes and the radiolabel in each sample was counted (FIG. 4). At 45 minutes the rats were sacrificed and the livers were counted for radio-label (FIG. 5).

As is shown in FIG. 4, approximately 8% of the ingested dose was found in the rats' blood 15 minutes after the water had been removed from the cage. The quantity in the rats' blood remained constant between 15 and 45 minutes. Liver uptake was approximately 8% at 45 minutes. Splenic uptake at 45 minutes was approximately 1% of the ingested dose (FIG. 5). The total absorption was approximately 17% (including blood, liver, and spleen).

Experiment 3—Hepatocyte Targeting with a Composition in Alloxan-Streptozotocin Treated Mice

Mice used in the present experiment were made diabetic by administering streptozotocin and alloxan. The diabetic animals were then divided into two groups. The control group (11 mice) was orally dosed with regular insulin. The experimental group (7 mice) was orally dosed with a composition comprising insulin and approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and approximately 1 mole percent poly[Cr-bis(N-2,6-diisopropylphenylcarbamoylmethyl iminodiacetic acid)] (wherein a known portion of the phospholipid component comprised ¹⁴C labeled phospholipid). Dosing was accomplished utilizing the water bottle dosing method described in Experiment 2.

After being made diabetic, rats in both groups were treated identically over a 7 day period and fed with plain food and plain water. Following this 7 day period, rats in the control group were treated for an additional 7 day experimental period with food and regular insulin in the available drinking water at 0.1 U/ml. Over the same 7 day experimental period, the experimental group was fed regular food with the composition of the invention available in the drinking water at 0.1 U/ml. At the end of each 7-day period, blood glucose was measured in a tail-vein sample of blood by a Beckman Blood Glucose Analyzer.

The pharmacologic efficacy of orally administered insulin in the group dosed with the above described composition is shown in FIG. 6. Mice receiving the composition had a statistically significant reduction in blood glucose on day seven (p<0.01) compared to mice receiving regular insulin, whose blood glucose was not altered at all.

Example 4 In Vivo Administration of Serotonin

The hepatic action of a composition comprising serotonin and approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and 1 mole percent of poly[Cr-bis(N-2,6-diisopropylphenylcarbamoylmethyl iminodiacetic acid)] was demonstrated in a type 2 diabetic dog (truncal vagotomy). The dog was fasted, and then anesthetized. Blood sampling catheters were placed in the hepatic and portal veins to enable simultaneous blood sampling. Glucose was infused into the portal system at a rate of 0.5 g/kg/hour. Next, the above described composition was administered intraduodenally in a single dose of 30 μg/kg body weight. Results are depicted in FIG. 7 and demonstrate that serotonin (also referred to as 5-hydroxytryptamine or 5-HT), administered intraduodenally as a composition of the invention is effective at low doses in converting a type 2 diabetic dog from hepatic glucose output to uptake during a portal glucose load.

Example 5 In Vivo Administration of Calcitonin

Normal, fasted, control rats were given a dose of salmon calcitonin via subcutaneous injection such that an initial 10% reduction in blood calcium was observed. Blood calcium levels were then measured for six hours post injection. An experimental group of rats was given the same effective dose of calcitonin by oral gavage, in the form of a composition comprising calcitonin and approximately 62 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, and approximately 16 mole percent cholesterol. Blood calcium levels were followed for six hours (FIG. 8). A blood calcium reduction of up to 20% was observed in the non-control rats. This difference was statistically significant (FIG. 8).

Example 6 Clinical Trial with Targeted Insulin in Type 2 Diabetes Mellitus Subjects

Capsules containing a composition of the invention were prepared. The composition comprised insulin as the therapeutic agent, gelatin, and approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and about 1 mole percent of the sodium salt of Biotin-HDPE. Each capsule contained 2 U of insulin.

Six well characterized Type 2 diabetes patients participated in the controlled study. The patients were maintained on their customary Type 2 oral anti-diabetes therapy. Study participants were also given either placebo capsules or the above described capsules 30 minutes before a 60 gram carbohydrate meal at breakfast, lunch and dinner. Blood samples were drawn at frequent intervals over a 13 hour period and the Incremental Area Under the Curve for the blood glucose values was calculated for each subject.

At 0.1 U/kg body weight/meal, the same dose that is frequently used with subcutaneous injection of insulin at a given meal, a statistically significant reduction in AUC for each of the three meals was observed. FIG. 10 depicts the results of the trial in graphical format.

Example 7 Insulin Concentration

Insulin U-500 contains 500 units of insulin/ml=0.5 units/1 μl

- Add 3.36 ml of U-500 insulin to 70 ml of constituent suspension in 18 mM phosphate buffer @ pH 7.01.
- (3,360 μl)*(0.5 units of insulin/μl)=1,680 units of insulin total in 73.36 ml
- (1,680 units of insulin)/(73.36 ml)=22.9 units of insulin/ml—or—34.35 units of insulin/1.5 ml
- Load insulin for 21 hours;
- Post loading, chromatograph 1.5 ml of sample over a 1.5 cm×25 cm column with Sepharose CL-6B gel equilibrated with 18 mM phosphate buffer @ pH 7.01
- 0% of free insulin recovered from column; The recovery of 0% of the total loaded insulin implies that 100% of the total “loaded” insulin is associated with a constituent of the composition.
- 34.35 units of insulin×100%=34.35 units of insulin bound or associated with the constituents of the invention.
  FIG. 11 depicts the above described chromatography. A trace showing the elution time of free insulin is included for purposes of comparison. As can be seen from the chromatogram, insulin is associated with the constituents of the invention and no free insulin is in solution. A preservative included with insulin does not associate with the constituents of the composition of the invention and is visible in the chromatogram.

Example 8 Oral Delivery of GLP-1

Rats were fasted overnight. Subsequently, 800 mg each of alloxan and streptozotocin were dissolved in 40 mL of PBS (pH 7, 0.01 M). The fasted rats were then treated immediately with a 0.5 mL IP dose to induce insulin deficiency. The animals were then stabilized overnight with water and food. Following stabilization, the rats were fasted overnight to deplete liver glycogen.

Subsequently, the rats were administered 1.5 g glucose/kg body weight and GLP-1 in the form of a GLP-1 associated with a composition comprising approximately 62 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, and approximately 16 mole percent cholesterol (“associated GLP-1”). In separate experiments, the amount of associated GLP-1 was varied. Liver glycogen was measured chemically at 2 hours post dosing.

As a control, unassociated GLP-1 was gavaged in place of associated GLP-1. In a separate control, GLP-1, in a dose similar to that orally gavaged, was injected intraperitoneally. As is shown in Table 3, below, substantially enhanced oral efficacy was observed for the associated GLP-1 versus non-associated GLP-1.

TABLE 3 Liver Treatment Dose GLP-1 mg/rat Glycogen mg/g liver Control Oral GLP-1 0.01 40 ± 22 Intraperitoneal GLP-1 0.01 59 ± 44 Oral Associated GLP-1 0.005 73 ± 56* Oral Associated GLP-1 0.01 90 ± 75* *p = 0.05 compared to Control Oral GLP-1

Example 10 Oral Thyroxine

Thyroxine is known to lower blood cholesterol and triglyceride levels. However, at the doses required to treat high cholesterol and triglyceride, thyroxine causes hyperthyroidism as an unwanted side effect. The goal of this study was to demonstrate that orally administered targeted thyroxine associated with a compound of the invention would act at the liver with the result of lowering blood lipids without inducing the unwanted hyperthyroidism.

Normal laboratory mice, on high caloric diets, were administered low oral doses (0.2 to 1.0 μg) thyroxine in the form of a composition comprising thyroxine and constituents generated from a mixture of lipid components comprising approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and approximately 1 mole percent of the sodium salt of Biotin-HDPE, a liver-targeting agent.

The mice, in groups of 4, were dosed daily by oral gavage for one week in a dose response study. Blood cholesterol and triglycerides were measured after one week treatment. Baseline values for cholesterol and triglycerides for all the groups were similar. The dose responses, shown in FIG. 13, demonstrates the efficacy of orally administered, hepatic targeted thyroxine associated with a composition of the invention. Blood levels of thyroid hormone did not increase with the dosing of hepatic targeted oral thyroxine, demonstrating the safety of the product.

Other published studies (Erion, M., et al., PNAS Sep. 25, 2007 vol 104, #39, pp 15490-15495) with hepatic targeted thyroxine analogs required doses at least 10 fold higher than those described herein to elicit similar reductions in blood cholesterol and triglycerides.

Example 11 Oral Interferon

A composition was prepared comprising interferon-α as the therapeutic agent and approximately 61 mole percent 1,2 distearoyl-sn-glycero-3-phosphocholine, approximately 22 mole percent dihexadecyl phosphate, approximately 16 mole percent cholesterol, and about 1 mole percent of the sodium salt of Biotin-HDPE.

Six patients with Hepatitis C, genotype 3, were treated with an aqueous suspension of the above described composition and Ribivirin daily for 8 weeks. The interferon-α dose in the aqueous suspension of the composition was 60,000 Units/day.

Hepatitis C viral loads were measured at the beginning of the study, then at weeks 1, 2, 4, and 8. See FIG. 14. The data demonstrates the ability of the aqueous suspension of a composision of the invention to lower viral load with a minimal dose of interferon. Side effects were likewise minimized.

Example 12

In an example of a covalent interaction, IgG (human immunoglobulin, mixture of antibodies) was covalently linked to MPB-PE to form a IgG construct. IgG is an antibody that is not normally orally bioavailable. In this embodiment of the invention, the lipids selected to form the composition of the invention included approximately 68 mole percent 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, approximately 19 mole percent dihexadecyl phosphate, approximately 10 mole percent cholesterol, and approximately 3 mol percent MPB-PE.

In order to form the composition of the invention, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, dihexadecyl phosphate, and cholesterol were microfluidized as set forth earlier herein to form constituents with an average size of between 50 and 60 nanometers. This suspension of constituents was then transferred to a round bottom flask that had been coated with a thin film of MPB-PE. The suspension was heated to about 62° C., with the temperature not falling below 60° C. or exceeding 65° C. The heated suspension was subsequently stirred for 15 minutes until all of the MPB-PE had been incorporated into the lipid construct.

Separately, IgG was reacted with a 10 fold excess of linker precursor XI to form XII, per Scheme III.

Compound XII was then purified using a 2.5×25 cm Sephadex G-25 column equilibrated with 18 mM phosphate buffer plus 1.0 mM EDTA buffer at pH 7.4. Next, the acetyl protecting group on compound XII was removed by stirring compound XII with 50 mM hydroxylamine hydrochloride in 18 mM sodium phosphate buffer containing 1.0 mM EDTA (pH 7.4) for 2 hours at ambient temperature. The resulting free thiol, XIII, was purified on 2.5×25 cm Sephadex G-25 column, as set forth for compound XII.

Immediately following purification, 200 μ-moles of compound XIII was mixed with 10 ml of the composition prepared earlier. The reaction mixture was stirred for 15 minutes, during which time compound XIII underwent a Michael reaction with the maleimide functionality of the MBP-PE incorporated in the lipid construct. The conjugation reaction was stopped, and excess XIII removed, by the addition of a 50× molar excess of N-ethylmaleimide.

Although the above example was described with respect to IgG, it is equally applicable to any therapeutic agent with a nucleophilic nitrogen.

Example 13 Administration of Covalent Oral IgG

Human IgG antibodies were covalently attached to a constituent of the invention, as described in Example 12. Subsequently, eight 250 gram laboratory rats were prepared with intra-duodenal catheters for the administration of covalent IgG. After an overnight fast, 5 ug of covalent IgG was infused into the duodenal catheter. The catheter was subsequently washed with 0.5 ml buffer. Blood samples were taken at 15, 30, 60 and 120 minutes to assay the plasma concentration of human IgG antibodies by ELISA reaction.

In a control experiment, 5 ug of free IgG was infused into the duodenal catheter. The catheter was subsequently washed with 0.5 ml buffer. Blood samples were taken at 15, 30, 60 and 120 minutes to assay the plasma concentration of human IgG antibodies by ELISA reaction. The results of both studies are shown in FIG. 12.

As can be seen in FIG. 12, covalent IgG provided enhanced plasma concentration of human IgG (AUC) as compared to free IgG. Likewise, covalent IgG enhanced Tmax—the time to maximum concentration, and Cmax—the maximum plasma concentration observed upon dosing. The enhanced efficacy of covalent IgG, as compared to free IgG, thus demonstrates the ability of a compound of the invention to enhance oral absorption of very large proteins into the systemic circulation.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims

1. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula I, wherein or NH2NH—;

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

“A” is

“J” corresponds to (CH2)a or

G1 is either H or SO3Na; and

“a” is independently, at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8.

2. The composition according to claim 1, wherein the linker precursor according to formula I is N-succinimidyl-3-(2-pyridyldithio)proprionate (“SPDP”), Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (“LC-SPDP”), Sulfosuccinimidyl 6-(3′-[2-pyridyldithio]-propionamido)hexanoate (“Sulfo-LC-SPDP”), 4-Succinimidyloxycarbonyl-methyl-a-[2-pyridyldithio]toluene (“SMPT”), 4-Sulfosuccinimidyl-6-methyl-a-(2-pyridyldithio)toluamido]hexanoate) (“Sulfo-LC-SMPT”), or 3-(2-pyridyldithio)propionyl hydrazide (“PDPH”).

3. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula II, wherein —HNC(O)CH2I, —CH2NHC(O)(CH2)aNHC(O)CH2I, —CH2HNC(O)CH2I;

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G1 is either H or SO3Na;

G2 is maleimidyl,

“Q” is optional and, when present, is C(O)(CH2)aNH;

“K” is optional and, when present, is —(CH2)a—; and

wherein “a” is independently, at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8.

4. The composition according to claim 3, wherein the linker precursor according to formula II is Succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (“SMCC”), Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (“Sulfo-SMCC”), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (“MBS”), m-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester (“Sulfo-MBS”), N-Succinimidyl[4-iodoacetyl]aminobenzoate (“SIAB”), N-Sulfosuccinimidyl[4-iodoacetyl]aminobenzoate (“Sulfo-SIAB”), succinimidyl-4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate (“SIAC”), succinimidyl 4-[p-maleimidophenyl]butyrate (“SMPB”), sulfosuccinimidyl 4-[p-maleimidophenyl]butyrate (“Sulfo-SMPB”), or succinimidyl-6-((((4-(iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)-hexanoate (“SIACX”).

5. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula III, wherein

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G1 is either H or SO3Na;

G4 is maleimidyl, —HNC(O)CH2I, or NHC(O)(CH2)aNHC(O)CH2I; and

“a” is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8.

6. The composition according to claim 5, wherein the linker precursor according to formula III is N-[g-maleimidobutyryloxy]succinimide ester (“GMBS”), N-[g-maleimidobutyryloxy]sulfosuccinimide ester (“Sulfo-GMBS”), succinimidyl-6-((iodoacetyl)amino)hexanoate (“SIAX”), or succinimidyl-6-(6-(((iodoacetyl)amino)hexanoyl)amino)hexanoate (“SIAXX”).

7. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula IV,

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

8. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula V, wherein

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

Z is independently optional at each occurrence, and, when present, (CH2)a; and

wherein “a” is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8.

9. The composition according to claim 8, wherein the linker precursor according to formula V is 4-(4-N-Maleimidophenyl)butyric acid hydrazide hydrochloride (“MBPH”), or 4-(N-maleimidophenyl)cyclohexane-1-carbonyl-hydrazide hydrochloride (“M2C2H”).

10. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula VI, wherein wherein G1 is either H or —SO3Na; and with the proviso that is G6 is —C(O)G7 only when G5 is —NO2 and that G5 is —NO2 only when G6 is —C(O)G7.

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G5 is selected from the group consisting of —C(O)G7, —C(O)NHNH2, —C(O)C(O)H, —C(O)NH(CH2)aNH2, —C(O)NH(CH2)aNHC(O)CH2I, —C(O)NH(CH2)aC(O)G7, —NO2, —(CH2)aNHC(O)G7, —NH(CH2)aC(O)G7, —(CH2)aSSC(O)G7, —C(O)NH(CH2)aSS(CH2)aC(O)G7, —(CH2)aC(O)G7, and —C(O)NH(CH2)aNHC(O)(CH2)aG9;

“a” is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, or 8;

G6 is selected from the group consisting —OH, —NO2, —H, and —C(O)G7;

G7 is

G9 is

11. The composition according to claim 10, wherein the linker precursor according to formula VI is N-Hydroxysuccinimidyl-4-azidosalicylic acid (“NHS-ASA”), N-hydroxysulfosuccinimidyl-4-azidosalicylic acid (“Sulfo-NHS-ASA”), sulfosuccinimidyl[4-azidosalicylamido]-hexanoate (“Sulfo-NHS-LC-ASA”), N-hydroxysuccinimidyl-4-azidobenzoate (“HSAB”), N-hydroxysulfosuccinimidyl-4-azidobenzoate (“Sulfo-HSAB”), N-5-azido-2-nitrobenzoyloxysuccinimide (“ANB-NOS”), N-succinimidyl-6-(4′-azido-2′-nitrophenylamino)hexanoate (“SANPAH”), N-sulfosuccinimidyl-6-(4′-azido-2′-nitrophenylamino)hexanoate (“Sulfo-SANPAH”), N-succinimidyl(4-azidophenyl)-1,3′-dithioproprionate (“SADP”), N-Sulfosuccinimidyl(4-azidophenyl)-1,3′-dithioproprionate (“Sulfo-SADP”), sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl-1,3′-dithiopropionate (“SASD”), 1-(p-azidosalicylamido)-4-(iodoacetamido)butane (“ASIB”), N-[4-(p-azidosalicylamido)butyl]-3′-(2′-pyridyldithio)propionamide (“APDP”), p-azidobenzoyl hydrazide (“ABH”), 4-[p-azidosalicylamido]butylamine (“ASBA”), p-azidophenyl glyoxal (“APG”), or sulfosuccinimidyl-4-(p-azidophenyl)butyrate (“Sulfo-SAPB”).

12. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula VIII, wherein wherein “a” is independently, at each occurrence, 1, 2, 3, 4, 5, 6, 7, or 8.

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G′ is either H or SO3Na;

G8 is selected from the group consisting of 2-nitrophenyl-5-azido and

13. The composition according to claim 12, wherein the linker precursor according to formula VII is sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3′-proprionate (“SAND”) or sulfosuccinimidyl 2-[7-amino-4-methylcoumarin-3-acetamido]ethyl-1,3′dithiopropionate (“SAED”).

14. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula VIII, wherein

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G1 is either H or SO3Na;

G8 is selected from the group consisting of 2-nitrophenyl-5-azido and

15. The composition according to claim 14, wherein the linker precursor according to formula VIII is sulfo-succinimidyl 7-azido-4-methylcoumarin-3-acetate (“Sulfo-SAMCA”).

16. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula IX, wherein

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

G10 is selected from the group consisting of maleimidyl and NC(O)CH2I.

17. The composition according to claim 16, wherein the linker precursor according to formula IX is benzophenone-4-iodoacetamide or benzophenone-4-maleimide.

18. An orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids through a linker derived from a linker precursor according to formula X, wherein G11 is selected from the group consisting of C(O)C(N2)H and C(N2)CF3.

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3 aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional reticuloendothelial system (“RES”) masking agent; and

an optional targeting agent,

19. The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of insulin, interferon, erythropoietin, parathyroid hormone, calcitonin, serotonin, rituximab, trastuzumab, uricase, tissue plasminogen activator, thymoglobin, a vaccine, heparin or a heparin analog, antithrombin III, filgrastin, pramilitide acetate, exanatide, epifibatide, antivenins, IgG, IgM, HGH, thyroxine, GLP-1, blood clotting Factors VII and VIII, IX, X, a monoclonal antibody, and glycolipids that act as therapeutic agents.

20. The composition of claim 1 wherein the lipids are 1,2 distearoyl-sn-glycero-3-phosphocholine, dihexadecyl phosphate, and cholesterol.

21. The composition of claim 20 wherein said 1,2 distearoyl-sn-glycero-3-phosphocholine is present in approximately 62 mole percent, said dihexadecyl phosphate is present in approximately 22 mole percent, and said cholesterol is present in approximately 16 mole percent, wherein, optionally, at least about 25% of the cholesterol is thiocholesterol.

22. A method of preparing an orally bioavailable composition comprising: wherein said at least one therapeutic or diagnostic agent is covalently bound to one or more of said one or more lipids either directly or through a linker derived from a linker precursor according to formula I, said method comprising the steps of:

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate;

at least one therapeutic or diagnostic agent;

an optional RES masking agent; and

an optional targeting agent,

a. selecting one or more of said lipids;

b. mixing said lipids to form a mixture of lipid-based constituents;

c. selecting said therapeutic agent;

d. reacting said therapeutic agent with a linker-precursor of formula I to form a therapeutic agent/linker conjugate; and

e. adding said conjugate to said mixture to form said composition.

23. An orally bioavailable composition comprising:

one or more lipids selected from the group consisting of MCC-PE, MPB-PE, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol, thiocholesterol, cholesterol oleate, dihexadecyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-2-mercaptoethanol, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt), and triethylammonium 2,3-diacetoxypropyl 2-(5-((3 aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate; and

at least one therapeutic agent selected from the group consisting of blood clotting factors VII, VIII, IX, Kallikrein, Kininogen, Hageman Factor (XII), plasma thromboplastin antecedent Factor (XI), tissue factor, Stuart Factor (X), accelerin (V), prothrombin (II), and fibrin stabilizing Factor (XIII).